SACHS
ASSOCIATES

2nd ANNUAL

NEUROSCIENCE INNOVATION FORUM

FOR BD&L AND INVESTMENT IN THERAPEUTICS AND TECHNOLOGY

6TH JANUARY 2019
MARINES' MEMORIAL CLUB
SAN FRANCISCO, USA

CONFERENCE GUIDE

www.sachsforum.com

SACHS ASSOCIATES ARE DELIGHTED TO WELCOME YOU TO THE:

2ND ANNUAL
NEUROSCIENCE INNOVATION FORUM
FOR BD&L AND INVESTMENT IN THERAPEUTICS AND TECHNOLOGY

6TH JANUARY 2019
MARINES` MEMORIAL CLUB, SAN FRANCISCO
UNITED STATES

Building on the success of our last year's forum we are pleased to announce the 2nd Annual Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and Technology to take place at the Marines' Memorial Club, San Francisco on the 6th of January 2019, a day before the JP Morgan meeting.

The program will cover BioPartnering for CNS, with industry keynotes and panels on AD, PD, Neuropsychiatry and Pain Management. Moreover there are panels on innovation in NeuroTech covering banking, device, diagnostics and software.

GENERAL INFORMATION

The registration desk will be open from 7.30am on January 6th, although you are welcome to join the event at any time. Please collect a copy of the agenda for information on timing and room allocation for each session.

Networking at the summit is facilitated by our online One-2-One meeting system, which is available to all participants. The One-2-One meetings are being held in Crystal Ballroom. Please bring with you a copy of your diary. Should you have any queries about your schedule, the Sachs team situated by the meeting tables is available for your assistance.

Wireless Internet connection is available throughout the venue for the duration of the event. Please ask for an access code at the registration desk.

There will be networking lunch, reception, and coffee stations set up in the rooms throughout the event.

REQUEST FOR PRESENTATIONS

Please use the agenda to mark off presentations that you are interested in and email your request to Silvia@sachsforum.com after the conference. We will endeavor to send you the requested presentations as soon as we have been granted permission to do so by that specific presenter.

Please note that we DO NOT have copies of the slides that are shown during the conference.

EVENTS DIARY

For the regular updates, sponsorship, presenting and attending opportunities and further information regarding any of our future events, please contact Silvia Kar on Silvia@sachsforum.com.

12TH ANNUAL EUROPEAN LIFE SCIENCES CEO FORUM
25TH - 26TH FEBRUARY 2019 • HILTON ZURICH AIRPORT HOTEL • ZURICH • SWITZERLAND

Back for its 12th Annual edition, this global bio-pharma industry forum addresses through its conference programme the main challenges for 2019 in investment, partnering and alliance management. Key players contribute their insights in panels which cover the macro picture as well as innovation in the different therapeutic sectors. The forum also features keynote speeches by KOL, about 60 selected corporate presentations from established (public and private) and emerging biotechs seeking to promote investment and partnering opportunities. We expect over 350 delegates to attend the event. This year, following our conference, in the afternoon of the 26th we will also host the 1st GoforIsrael @ 12th Annual Sachs ELSCEO Forum. More information is available HERE.

5TH ANNUAL IMMUNO-ONCOLOGY BD&L AND INVESTMENT FORUM
31ST MAY 2019 • WALDORF ASTORIA CHICAGO HOTEL • CHICAGO • USA

Taking place on the first day of ASCO, the 5th Annual Immuno-Oncology BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment. The event will focus on biotech partnering and investment giving you an excellent opportunity to network with executives from top pharma, biotech companies, and investors. We expect around 250 delegates and about 30 presentations by listed and private biotechnology companies seeking licensing & investment.

19TH ANNUAL BIOTECH IN EUROPE FORUM
15TH - 16TH OCTOBER 2019 • CONGRESS CENTER BASEL • SWITZERLAND

The 19th Annual Biotech in Europe Forum is recognised as the leading international stage for those interested in investing and partnering in the biotech and life science industry. This highly transactional event draws together an exciting cross-section of early stage/pre-IPO, late stage and public companies, with leading investors, analysts, money managers and pharma licensing executives. We expect over 700 delegates and 100 presenting companies with additional 20 brief presentations by seed companies.

Supported and designed by leading figures within Europe's pharmaceutical and biotech industry, the forum will be held for the sixth time in Basel to be close to the largest biopharma hub in Europe and the Congress Center provides meeting space capable of handling several thousand One-2-One meetings as well as significant exhibition space.

7TH ANNUAL MEDTECH & DIGITAL HEALTH FORUM
16TH OCTOBER 2019 • CONGRESS CENTER BASEL • SWITZERLAND

This year we will be holding our 7th Annual MT&DH Forum on the second day of our 19th Annual BEF, on the 16th of October at the Congress Center Basel. The programme is designed to highlight the latest industry developments and showcase emerging and innovative technology companies seeking finance and partnerships. The delegates are comprised of Healthcare, MedTech, Healthcare IT and Digital Health companies as well as consultants, bankers and corporate & financial investors. We expect over 250 delegates and 25 presenting companies, plus around 20 presentations by seed companies.

ONLINE ONE-2-ONE MEETING SYSTEM AVAILABLE AT ALL SACHS EVENTS

In order to offer the best possible provision for networking opportunities and dealmaking Sachs Associates provides delegates access to our online One-2-One meeting system, allowing you to set up, accept or decline private One-2-One meetings with other conference attendees. These meetings last for 20 minutes in duration. Individual passwords and logins are provided to allow immediate access and ensure full security.

KEYNOTE SPEAKERS

NI Research

HARRY TRACY

President

Dr. Tracy is the founder and President of NI Research. Since 1995, NIR has been the leading publisher of independent analysis and commentary regarding the neurotherapeutics area. NIR's bimonthly publication, NeuroPerspective, is utilized by pharmaceutical companies and investment professionals around the world, and is known for its willingness to directly address the often painful realities of the CNS area, albeit with style and humor. NIR also publishes the annual NeuroLicensing, and NIR's Second Opinion service offers consulting services regarding strategic planning and licensing to pharmaceutical companies ranging from the largest of major pharma firms to small startups.

Dr. Tracy's background includes twenty-five years of experience as a clinician and consultant in a variety of psychiatric and neurological settings. He received his PhD from the University of Miami, and completed his clinical training at Massachusetts General Hospital/ Harvard Medical School.

Emerald Health Pharmaceuticals, Inc.

JIM DEMESA

Chief Executive Officer

Dr. DeMesa is a former practicing physician and has 29 years of experience in biotech leadership, product development, clinical and regulatory management, and partnerships with pharmaceutical, biotech, and medical device companies. He has lead the advancement of product development from preclinical to clinical development, regulatory approval, and commercialization. He is the former CEO of two public biotech companies and currently serves as director for two biotech companies. Dr. DeMesa received BA in Chemistry, M.D., and M.B.A. degrees from the University of South Florida.

SPEAKERS

Click Therapeutics, Inc.

AUSTIN SPEIER

Chief Strategy Officer

Austin Speier is a healthcare consultant with over 10 years of experience supporting innovation in the life sciences; he has extensive FDA regulatory experience spanning over 250 life sciences companies and many first-in-class digital products. As Chief Strategy Officer for Click Therapeutics Mr. Speier establishes regulatory strategy while providing crucial industry knowledge and insight. Austin Speier was previously the Vice President, Emerging Technologies at Precision for Medicine, where he advised on the design and execution of development and go-to-market strategies for complex or first-in-class products, especially those with a digital software-based component. In addition, he worked closely with early-stage and venture-backed clients to identify and address the most critical scientific, clinical, regulatory, and reimbursement issues on the pathway to market for their products. Mr. Speier's experience spans a range of product categories and therapeutic areas including work with numerous cardiovascular, neurology, wound care, gastroenterology, oncology, drug delivery, women's health, software, mobile health, diagnostic, and consumer products. He previously conducted research at the Brigham & Women's Hospital Center for Neurodegeneration and Disease, where he focused on characterizing the molecular and cellular pathology of Alzheimer's Disease. Mr. Speier holds an A.B. cum laude in Biology from Harvard College, where he also completed the interdisciplinary Honors Neurobiology program to receive a certificate in Mind, Brain, and Behavior Studies.

Excellentia Global Partners

BETH JACOBS

Managing Partner

Beth Jacobs currently serves as Managing Partner of Excellentia Global Partners, a global life sciences investment bank, founded in 2008. Engagements focus on proteomics, innovative therapeutics, and companies focused on innovation in their approach to solving problems in medicine. Beth is deeply involved in the biotech community, working with both VC and public investors to fund companies.

Prior to establishing Excellentia Global Partners, Beth was a General Partner at Bio-IB, a life science-focused investment bank in New York.

Current Board appointments include:

- Genomic Vision (GV Euronext Exchange /Paris – publicly-listed company using innovative methods to explore and analyze genetics for rare diseases) - Supervisory Board member (Board of Directors is accountable to the Supervisory Board, acting as the senior guiding entity for the company)
- New York Academy of Sciences: Board of Governors, Chair of the Investment Committee, Governance and Executive Committees
- Susan G. Komen for the Cure,: founding Global Ambassador
- William J. von Liebig Foundation for Medical Research: Director
- The Metropolitan Museum of Art: Friends Committee and Visiting Committee of Ancient Near East Department
- Harvard Kennedy School of Government Womens Leadership Board
- EF Foundation: Board of Directors of , a global educational services company based in Stockholm and Cambridge, Mass
- NAUTILUS Magazine: Advisory Board
- Budapest Festival Orchestra: Vice Chairman of the Board (7 years, ended 2014)

Beth has served in senior executive roles in her twenty-five years of experience in both investment banking and in the corporate sector. Prior to 2003, Beth served as Senior Vice President for Laureate Education (NASDAQ: LAUR), a $3 billion market cap company in the education sector.

BlackThorn Therapeutics

BILL MARTIN

President & COO

William J. Martin, PhD is a founding executive team member of BlackThorn Therapeutics where he currently serves as President and Chief Operating Officer, having served previously as Chief Scientific Officer and Head of Research and Development since the Company's inception. BlackThorn is a clinical-stage biopharmaceutical company discovering and developing targeted treatments for neurobehavioral disorders based on novel, integrative approaches to patient phenotyping. Prior to joining BlackThorn, Dr. Martin held multiple leadership positions at Theravance Biopharma, including leading the company's research portfolio planning initiative and serving as a member of the strategic partnership team and project team leader for an advanced clinical-stage central nervous system (CNS) program. He began his career at Merck where he contributed to the strategic direction of Merck's Neuroscience franchise and chaired multiple CNS development teams. Bill serves on the Advisory Council for Brown University's Carney Institute for Brain Science and is an At-Large Member of the Coalition for the Life Sciences Board of Directors. He graduated from Swarthmore College, earned a Ph.D. from Brown University, and conducted postdoctoral research at the Keck Center for Integrative Neuroscience at the University of California, San Francisco.

Cerevance, Inc.

BRAD MARGUS

Chief Executive Officer

Brad Margus recently raised $43 million in equity and non-dilutive cash to start Cerevance, identify new targets and advance promising therapeutics for brain-related diseases. Before Cerevance, he started Envoy Therapeutics, a CNS drug discovery company, and then sold it to a global pharmaceutical company in less than three years for 15x the invested capital. Before Envoy, Margus was co-founder and CEO of Perlegen Sciences, a leader in analyzing genetic variation. In addition, Margus leads a non-profit foundation that orchestrates research on a rare disease two of his sons have that causes neurodegeneration, cancer and immune system problems. He also currently serves on several other corporate and non-profit boards as well as NIH advisory committees.

NEMUS Bioscience, Inc.

BRIAN MURPHY

Chief Executive Officer

Dr. Murphy has more than 15 years of experience in drug development and evaluation. Most recently he served as the Chief Medical Officer of Eiger Biosciences, and prior to that held the same position at Valeant Pharmaceuticals International (VRX). Dr. Murphy has also served as a Medical Director at InterMune, Inc. (ITMN), and Hoffmann-LaRoche, as well as Assistant Professor of Medicine at New York Medical College and Director of the Clinical Strategies Programs at St. Vincent's Hospital in New York City. Board-certified in internal medicine, Dr. Murphy earned his MD, MPH (general public health), and MS (pharmacology) degrees from New York Medical College and is a graduate of the Harvard School of Public Health (MPH in Health Policy and Management). He earned his MBA at the Columbia University Graduate School of Business.

PJT Partners

BRUCE LEUCHTER

Managing Director, Healthcare M&A

Dr. Bruce Leuchter is a Managing Director at PJT Partners where he provides M&A and capital markets advisory services to companies in the life science industry with a focus on the biotechnology sector. Dr. Leuchter is a physician by training and Neuropsychiatrist by specialty. He completed residency training in Neurology and Psychiatry at New York Presbyterian Hospital and Weill Cornell Medical College and is a Dipolmate of the American Board of Psychiatry and Neurology. Dr. Leuchter served as Director of Clinical Neuropsychiatry at Weill Cornell Medical College and maintains a faculty appointment of Clinical Assistant Professor of Psychiatry. Dr. Leuchter's financial services experience, prior to joining PJT Partners, includes roles in equity research and investment banking at Goldman Sachs and Credit Suisse, respectively. Given his background in neuroscience, he frequently advises companies developing technologies for diseases of the brain and nervous system. Dr. Leuchter co-founded Click Therapeutics, a digital medicine company which engineers, validates and commercializes digital therapeutics across disease areas with a focus on neuropsychiatry. He serves as a member of the Scientific Advisory Committee for the Daedelus Fund for Innovation at Weill Cornell Medical College, and on the Leadership Council of the Life Science Institute at the University of Michigan.

Oryzon Genomics S.A.

CARLOS BUESA ARJOL

Founder & CEO

He is a specialist in the Biotech Industry. Dr Buesa is BSc in Biology and got his PhD in Biochemistry (Molecular Biology) from the University of Barcelona, Spain. He was EU post-doctoral fellow in the Faculty of Medicine at the University of Ghent in Belgium and later Senior Investigator at the Flemish Institute of Biotechnology (VIB). He has also taken the executive education programme (PADE) at the IESE Business School in Barcelona and several other additional educational programs in finances. In 2000, he founded Oryzon, where, since inception, he has served as CEO and Chairman of the Board.

Under his leadership the company has got +65M € in several equity funding rounds +70 M € in non dilutive funds. After a transforming partnering deal of +$500 M with Roche in 2014, Dr Buesa leaded Oryzon to become a public company in 2015 in the Madrid Main Stock exchange. Through this listing in the Spanish market, the company secured $36M in the period, (€16,5M ($19M) in equity complemented with €15.5M debt ($17M)). In 2016, Oryzon was selected as one of the 3 Finalists in healthcare for the 7th Annual Most Innovative EU Biotech SME Award, a contest that congregated 41 companies from 13 European countries. In 1Q2017 he led a successful 18.2M€ Pipes ($20m) offering that included institutional investors specialized in healthcare and life sciences from the US, Spain and rest of Europe, In 2018 he led an additional 13M€ Pipe further reinforcing and diversifying the Company's shareholder base.

The company has evolved from being a Genomics R&D oriented company in its early days to a clinical stage biopharma company highly specialized in epigenetics. With a strong focus on one of the most promising targets of the field, the histone demethylase LSD1, the two most advanced molecules ladademstat and Vafidemstat are being explored currently in five Phase IIA trials in Oncology and in CNS respectively. These, and the rest of its pipeline, place today Oryzon at the forefront of the global Epigenetics space.

Novartis Pharma AG

CHARLES BAILEY

Head, Neuroscience BD&L

Charlie Bailey leads business development activities for the Neuroscience portfolio at Novartis Pharmaceuticals, with a focus on clinical stage assets across neurology, psychiatry and neuromuscular diseases. A broad CNS portfolio at Novartis encompasses conventional small and large molecules as well as gene therapy and digital therapeutics. Charlie has been closely involved in transformative deals including partnership with Amgen in Migraine and Alzheimer's, acquisition of Multiple Sclerosis product rights from GSK and company acquisition of AveXis and Spinifex Pharmaceuticals.

During 16 years of work in business development, Charlie has been responsible for transactions, search and evaluation and alliance management with a focus on neuroscience and oncology. Prior to his current role, he was responsible for licensing and M&A in Novartis Molecular Diagnostics. He also led R&D out-licensing activities in Roche Partnering and completed several oncology licensing deals in roles at Roche and Mundipharma International.

Oscine Therapeutics / ARCH Venture Partners

CHRISTINA TROJEL-HANSEN

CEO / Venture Partner

Christina Trojel-Hansen, Ph.D., is CEO of a pioneering CNS focused cell therapy start-up, Oscine Therapeutics and Venture partner with ARCH Ventures. Christina led the launch of Oscine as investor at Novo Holdings, a leading healthcare investment firm committed to helping exceptional scientists build the next generation of healthcare companies. During her time at Novo, Christina has been spinning out several projects. Prior to joining Novo Holdings, Christina served as Senior Business Development manager in Novozymes' Business Creation and M&A division leading teams focused on building new strategic platforms. Additionally, Christina has worked as patent agent at Zacco and as business analyst at Lux Research advising leading tech companies on a range of issues related to emerging technologies and business development. Christina has also been serving as start-up mentor at Indiebio (CA) and Breakout Labs (CA).

Christina has a background in the field of nanobiotechnology and cancer drug discovery. She completed her post-doctoral training at the leading european cancer Centre, Institute Gustave Roussy (INSERM) within the field of immuno-oncology. Christina holds a PhD from University of California, Berkeley and an MSc from the iNANO Centre at University of Aarhus.

Christina has received several awards and she was in 2017 nominated as one of Denmark's top business talents.

Neurotrope BioScience, Inc.

DANIEL ALKON

President & CSO

Dr. Alkon has served as President and Chief Scientific Officer of Neurotrope since September 2016. A leader in the field, Dr. Alkon comes to Neurotrope after 30 years directing programs on the molecular basis of associative memory at the National Neurologic Institute of NIH, and another 15 years as the Founding Scientific Director of the Blanchette Rockefeller. Neuroscience Institute where he and his team developed neurorestorative therapeutics for degenerative disorders of the central nervous system. He also served as the Toyota Chair of Neurodenerative Diseases and Professor of Neurology at West Virginia University before joining Neurotrope.

An internationally recognized pioneer in research on brain-based neural networks, the molecular basis of memory, and degenerative brain disorders, he has authored hundreds of scientific articles as well as several books, including Memory Traces in the Brain by Cambridge University Press, and the popular book Memory's Voice by Harper Collins.

Dr. Alkon received his B.A. from the University of Pennsylvania, and his M.D. at Cornell University, after which he interned at the Mt Sinai Hospital in New York.

Dolby Family Ventures

DEANNA BELSKY

Associate

Deanna currently works at Dolby Family Ventures as an Associate where she is responsible for diligence efforts and portfolio management across the life sciences sector with a focus on neuroscience. Dolby Family Ventures invests in accelerating the path to a cure for Alzheimer's disease. The portfolio includes novel disease-modifying therapeutics, diagnostics, and technologies that facilitate better science in clinical trials and basic research.

Prior to joining the Dolby Family Ventures team, Deanna worked at both a biotech hedge fund and a life sciences consulting firm where she conducted scientific, clinical, and commercial diligence around novel therapeutics. Before that, she served as a postdoctoral fellow at Stanford University where she studied molecular mechanisms of neurodegeneration. Deanna received her PhD from Rockefeller University and her BS in Biochemistry and BA in Asian Studies from Indiana University of Pennsylvania

Bionomics Ltd.

DEBORAH RATHJEN

Chief Executive Officer

Dr Rathjen joined Bionomics in 2000 from Peptech Limited, where she was general manager of business development and licensing. Dr Rathjen was a co-inventor of Peptech's TNF technology and leader of the company's successful defence of its key TNF patents against a legal challenge by BASF.

Dr Rathjen has significant experience in company building and financing, mergers and acquisitions, therapeutic product research and development, business development, licensing and commercialisation.

Dr Rathjen has been recognised both in Australia and internationally through awards and honours including the 2004 AusBiotech President's Medal, 2006 Flinders University Distinguished Alumni Aware, 2009 BioSingapore Asia Pacific Biotechnology Woman Entrepreneur of the Year, 2009 Regional Finalist Ernst & Young, Young Entrepreneur of the Year, 2014 Woman Executive of the Year BioPharm Industry Awards. In 2015 Dr Rathjen was included in the Top 50 most influential Australian business women by The Australian newspaper.

Aisling Capital, LLC

DENNIS PURCELL

Founder & Senior Advisor

Mr. Purcell is the original Founder of Aisling Capital LLC and currently serves as a Senior Advisor to Aisling. Previously, he served as the Senior Managing Partner. Prior to Aisling Capital, Mr. Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist, "H&Q") for over five years. While at H&Q, he was directly involved with over two hundred completed transactions and supervised over $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology and medical products industries. During his tenure, BioWorld and other industry publications cited H&Q as the leading underwriter of life sciences securities. Prior to joining H&Q, Mr. Purcell was a Managing Director in the Healthcare Group at PaineWebber, Inc.

Mr. Purcell is a frequent commentator on the industry and has been honored in the "Biotech Hall of Fame" by Genetic Engineering News, named to the Biotechnology All-Stars list by Forbes ASAP, honored as one of the top 50 Irish-American businessmen and cited as one of the top 100 contributors to the biotechnology industry.

Mr. Purcell has served as a director of Aton Pharma, Bridge Pharmaceuticals, Cengent Therapeutics, Dynova Laboratories, Paratek Pharmaceuticals, Valentis and Xanodyne Pharmaceuticals. He has served as a member of the Advisory Council at Harvard Medical School, the Board of Directors of the Biotechnology Industry Association, as well as the New York Biotechnology Association, the Irvington Institute and on the Board of L.E.K. Consulting. He currently sits on the board of Real Endpoints, Summus Global, Inc., Life Science Leader Magazine –Editorial Advisory Board, NY BIO Association and is a member of The University of Delaware Investment Visiting Committee Member.

Mr. Purcell received his M.B.A. from Harvard Business School and his B.S. in Accounting from the University of Delaware.

Allergan

DON FRAIL

SVP Research and External Science & Innovation, NTS

Don joined Allergan in 2014 and leads many of the preclinical efforts and clinical pharmacology for the organization and the External Science & Innovation (ESI) group within R&D, the group that partners with Business Development to evaluate and implement partnerships, licensing, and acquisitions. He has been involved in most Allergan deals completed since 2015 and sits on numerous JSCs. He also chairs the Allergan governance committee for all pre-POC development programs. With over twenty years of pharmaceutical and academia R&D and management experience, Don has been involved in a variety of pre-clinical drug discovery and Ph1/Ph2 clinical research areas and environments, including the entry of more than 25 compounds into development.

Cello Health BioConsulting, previously Defined Health

ED SALTZMAN

Executive Chairman

Ed Saltzman is President and Founder of Defined Health, now known as Cello Health BioConsulting, a leading strategic business development advisory firm serving senior executives in pharma, biotech and investment sectors. Leveraging 25+ years of experience consulting for biopharma companies, he provides guidance to Cello Health BioConsulting's senior project leadership who work with clients across multiple therapeutic areas. Ed is an in demand speaker on industry issues and has been recognized widely as an early "spotter" of key trends that go on to have significant impact within the life sciences industry, especially as these pertain to the licensing and business development field. He notably coined the term "Proof of Relevance," to describe indisputable demonstration of clinical and economic value in drug development. He is a recent recipient of the LES Frank Barnes Mentoring Award for his contributions to education in the life sciences sector. Ed is an advisor to the Israel Biotech Fund, and a member of the Licensing Executives Society (LES) and the New York Pharma Forum. He is a graduate of New York University.

Atentiv, LLC

ERIC GORDON

Founder, Chairman & CEO

As Founder/CEO, Eric has built seven biopharmaceutical, drug delivery and medical device companies. His success is based on the consistent theme of recognizing early breakthrough scientific concepts and their commercial applications. He has personally invested, developed and executed profoundly impactful development, market and growth strategies. Emerging from his experience is a tested, repeatable model for establishing the strategy, key resources, infrastructure, relationships and financing to enable rapid commercialization, scaling and growth. He has managed multiple products through FDA marketing approval or clearance. He has raised $124M from venture, angel and family office sources, $101M from two IPOs and $660M+ in strategic pharmaceutical company collaborations. Cumulative post money valuations following financings reached $1.7+B. Investor exits on six closed transactions averaged 8.3 times paid-in capital. Two companies reached annual revenues of $500+ and $800+ million.

Over 30+ years, he has co-initiated, driven and managed through full development and/or full global commercialization seven startup companies in pediatric, adult and traveler's vaccines (Connaught Labs -now Sanofi-Pasteur, and Virogenetics); in combinatorial chemistry for drug discovery (ArQule); in clinical genomics (Ardais); in drug-delivery for endometriosis (Combinent); in HDL/CHD therapeutics (Cardium);and in behavioral health care/ADHD diagnostics (BioBehavioral Diagnostics and now Atentiv).

He began his career with Arthur Andersen & Co. and served as VP and CFO at Sterling Drug and Glenbrook Labs. Eric holds business degrees from Syracuse University, the University of Pennsylvania, The Wharton School.

ProMIS™ Neurosciences, Inc.

EUGENE WILLIAMS

Executive Chairman

Gene Williams is a 35 year veteran of the biotech industry with a track record of entrepreneurial success and significant roles in large companies. As the Executive Chairman of ProMIS Neurosciences, a publicly traded TSX biotech company developing best in class precision therapies for Alzheimer's disease, Gene drove the strategic turnaround that led to ProMIS's current direction and portfolio. Prior to ProMIS, he was the CEO of Dart Therapeutics (now called Akashi), an Orphan Disease drug development company focused on Duchenne Muscular Dystrophy. As an SVP at Genzyme, Gene held senior roles in commercialization, drug development, and deal making. He was also a founder and director of Adheris, which became the largest company in the patient adherence area. He started his career a strategy consultant at Bain and Corporate Decisions Inc. (a Bain Spin off, now part of Oliver Wyman), where he was co-Head of Healthcare and spent extensive time on speeding and improving the drug development process and on commercialization strategies. Mr. Williams holds a B.A. from Harvard University and an M.B.A. from Harvard Business School.

Engage Therapeutics, Inc.

GREG MAYES

President & CEO

A biopharma leader with more than 20 years of experience in oncology, Greg became involved in the epilepsy community following his teenage son's epilepsy diagnosis in 2014. Leveraging his drug development experience and deep roots in the pharmaceutical industry, Greg founded Engage Therapeutics in 2017 to develop what could be the U.S.'s first seizure rescue inhaler.

Greg previously served as President of Unigene Laboratories, Inc. and subsequently as Chief Operating Officer of Advaxis Immunotherapies, a New Jersey-based biotech company developing immuno-oncology therapies for patients with hard-to-treat cancers through its bacterial vector system, Lm Technology™. He played an integral role in the company's growth, helping to secure more than $200 million in funding and negotiating partnerships with companies such as Amgen, AstraZeneca and Merck & Co., Inc.

A lawyer by training, Greg served as a As ImClone's General Counsel and played a key role in managing multiple clinical and regulatory activities that led to the 2008 acquisition by Eli Lilly for $6.5 billion. Earlier in his career, Greg was responsible for providing legal advice to the AstraZeneca oncology franchise as senior counsel and he started his biopharma legal career at the national law firm of Morgan Lewis. Greg holds a Bachelor of Science degree from Syracuse University and a JD from Temple University School of Law.

Johnson & Johnson Innovation

GUY SEABROOK

Vice President & Global Lead, Neuroscience External Innovation

Guy joined Janssen Pharmaceutical Companies of Johnson & Johnson in 2012 and is currently based at the J&J Innovation Center, South San Francisco, California. His role as the Global Lead for Neuroscience External Innovation is to create and implement the external innovation plan to deliver the Neuroscience Therapeutic Area R&D Strategy. He has 27 years of drug discovery experience that includes preclinical research on marketed products and candidates in clinical development. Previously, Guy was part of Eli Lilly's Global External Research & Development organization where he led the GER&D team for the Lilly Bio-Medicines Business Unit. Formerly, at Merck & Co, he was the Head of the West Point Department of Alzheimer's disease Research. Guy graduated with a PhD in Zoology from the University of Nottingham UK (1987), and completed his postdoctoral research at the University of Miami School of Medicine USA. He is a member of the British Pharmacological Society, The Physiological Society UK, and Biophysical Society, and has published over 90 peer reviewed papers and patent filings in the field.

Neurotech Reports

JAMES CAVUOTO

Editor & Publisher

James Cavuoto is editor and publisher of Neurotech Business Report and the founder of Neurotech Reports. He was the lead author of "The Market for Neurotechnology," a market research report published by Neurotech Reports. Cavuoto was previously the founder of Micro Publishing Press, Inc., a publishing company that helped pioneer the market for electronic publishing, digital imaging, and computer graphics. He holds a degree in biomedical engineering from Case Western Reserve University, where he studied under pioneers in the field of functional electrical stimulation. He has also studied human factors engineering at University of Southern California in Los Angeles. Cavuoto spent three years as a member of the technical staff at Hughes Aircraft Company in Los Angeles, where he worked on simulation, training, and publication products produced for the U.S. Department of Defense. Cavuoto was an adjunct professor at Rochester Institute of Technology and the author of eight books on computer graphics, electronic publishing, and digital imaging. He is a member of the IEEE Engineering in Medicine and Biology Society. He has authored a chapter in the textbook Neuromodulation (Elsevier), as well as articles in Journal of Neural Engineering, Medical Device Daily, IEEE Spectrum, MX magazine, and the International Journal of Medical Marketing.

Boehringer Ingelheim Venture Fund USA, Inc.

JAMES KASUBOSKI

Senior Director

James received his Ph.D. in Cellular and Molecule Biology from the University of Notre Dame. He then completed two post-doctoral fellowships, one at the Salk Institute for Biological Sciences focused on building experimental microscopes and the second in Pfizer's Neuroscience research unit focused on neurodegeneration and stem cell technology development. While at Pfizer he completed Flagship Pioneering's Fellowship program focused on creating new and innovative life science companies. He will be working closely with both the US and the European Venture teams on investing in new life science companies.

5AM Ventures

JAMIL BEG

Principal

Jamil M. Beg joined 5AM Ventures in 2017 as a Principal. Prior to 5AM, Mr. Beg was at Sage Therapeutics (NASDAQ: SAGE) where he contributed to building the company through business development, corporate strategy, medical affairs, health economics & outcomes research and commercialization roles. Previously, Mr. Beg was an investment professional at Quaker Partners and contributed to investments in the firm's portfolio companies including EKR Therapeutics (acquired by Cornerstone Therapeutics), Transave Inhalation Therapeutics (acquired by Insmed), NuPathe (NASDAQ: PATH, acquired by Teva) and Cempra (NASDAQ: CEMP). Mr. Beg started his career at Cambridge Pharma Consultancy (acquired by IMS Health) with a focus on pricing, market access and health economics outcomes research strategies for the biopharma industry. Mr. Beg earned his B.S.E. in Bioengineering and Master of Biotechnology degrees from the University of Pennsylvania. He earned his M.B.A. in Healthcare Management and Entrepreneurial Management from The Wharton School of the University of Pennsylvania where he was a recipient of the Henry J. Kaiser Family Foundation Merit Award.

Oppenheimer & Co. Inc.

JAY OLSON

Executive Director and Senior Analyst in Biotechnology

Jay Olson is Executive Director and Senior Analyst covering Biotechnology. Prior to joining Oppenheimer, Jay covered SMID-cap names and worked on the Large Cap Pharmaceuticals team at Goldman Sachs for 4 years after 4 years on the #1 II-ranked Large Cap Pharmaceuticals team at Sanford Bernstein. Prior to Wall Street, Jay spent 18 years in the pharmaceutical industry, working mostly for Pfizer in finance, marketing and business development. Jay received an M.B.A. in Finance and an M.S. in Chemical Engineering both from MIT, and a B.S. in Chemical Engineering from Tufts University. He also holds the CFA designation.

Eli Lilly and Company

JENNIFER LAIRD

Vice President, Search & Evaluation – Pain & Neurodegeneration

Jennifer Laird, Ph.D., D.Sc. is VP, Search & Evaluation Pain & Neurodegeneration at Eli Lilly and Company, based at Lilly's European Headquarters near London, UK. The Search & Evaluation team complements Lilly's internal R&D efforts by evaluating and in-licensing or acquiring assets and technologies and by collaborating with external partners to advance molecules through discovery and development. Dr. Laird joined Lilly in 2012; prior to that, she held various leadership roles at AstraZeneca, in academia and Merck. Dr. Laird received doctorates from Bristol University and University of Alicante, Spain, serves as an Editorial Board member of European Journal of Pain and holds an honorary appointment as Professor of Pharmacology at McGill University, Canada.

Purdue Pharma L.P.

JOHN RENGER

VP, Head of R&D and Regulatory Affairs

Dr. John Renger, V.P., leads R&D and Regulatory Affairs at Purdue Pharma. He is responsible for overseeing end-to-end pipeline activities including discovery, preclinical toxicology, PK/DM, clinical pharmacology, statistical modeling, clinical development, clinical operations, and regulatory drug approval activities. His responsibilities also include company, therapeutic, and functional strategy, executive committee leadership, budgeting, business development, and business and clinical operations activities. With a broad 18-year drug discovery and development background, Dr. Renger has been successful in leading a wide range of R&D teams that have brought forward more than 35 molecules into clinical development across more than 17 mechanisms of action and in multiple disease areas including clinical studies in chronic and acute pain, AD, adult ADHD, motor symptoms of essential tremor, schizophrenia, and chronic insomnia.

NeuroRx, Inc.

JONATHAN JAVITT

Founder, Chairman & CEO

Jonathan serves as Chairman and CEO of NeuroRx, Inc., which is developing the first oral FDA-designated Breakthrough Therapy for suicidal depression and PTSD. His professional background spans 30 years of combining clinical understanding with expertise in drug and medical device development, health information technology, health policy, and health economics. He began his career as a Professor of Ophthalmology and Public Policy at Johns Hopkins and Georgetown Universities and remains an adjunct member of the Johns Hopkins faculty.

Jonathan was a pioneer in the use of patient-reported outcomes and health economic research in drug and device development. He has served on drug and device development teams for Merck, Pharmacia, Pfizer, Bayer, Allergan, Alcon, and Eyetech, where he helped to pioneer the integration of pharmacoeconomic outcomes and patient quality of life into the drug and device clinical trials and product approvals. His experience includes regulatory expertise in FDA and CE compliance with the drug and device approval process and quality system management. He has been a founder of 6 health informatics and analytics companies that have gone on to successful public acquisitions: Healthcare Computer Associates (NYSE: SMSI), NextGen (Nasdaq:QSII), Certitude (NYSE:UNH), Active Health Management (NYSE:UNH), First Gateways (NYSE:DGX) and Coderyte, Inc., (NYSE:3M), and Telcare, Inc., funded by Qualcomm Ventures, Sequoia Capital, and Norwest Venture Partners. Most recently, he has founded NeuroRx, Inc., a clinical stage pharmaceutical company targeting the brain's NMDA receptor for treatment of acute suicidal crisis in patients with depression. In the policy arena.

Syndesi Therapeutics SA

JONATHAN SAVIDGE

Chief Executive Officer

Jonathan joined Syndesi Therapeutics in February 2018 as founding CEO. Prior to this, he spent 4 years leading business development for the biotech company Proximagen in the UK. While at Proximagen, Jonathan led a collaboration with Roche to develop a Phase II program and a collaboration on an ion channel program in CNS. He previously spent 5 years with Evotec as VP Business Development working closely with the internal CNS R&D team, executing collaboration deals on clinical phase CNS assets in AD and depression with Roche and Janssen. Jonathan has also worked as a business development consultant with several other biotech companies including Bicycle Therapeutics, Syntaxin (acquired by Ipsen) and ReNeuron. Jonathan has a scientific background, holding a research position at Novartis in pain research following his PhD in Neuropharmacology.

CV Sciences, Inc.

JOSEPH DOWLING

Chief Executive Officer

Mr. Dowling was appointed as Chief Executive Officer of the Company in May 2018. Prior to his appointment as CEO, Mr. Dowling held the position of CFO with the Company since 2014. Prior to 2014, Mr. Dowling held numerous senior positions including President and Chief Financial Officer of MediVas, LLC, a biotechnology company focused on drug formulation and delivery from 2005 to 2013 where he led day-to-day operations, drug research and development, product development and commercialization and strategic alliance building including license agreements with Pfizer, Merck, Wyeth, DSM, Guidant and Boston Scientific. Mr. Dowling also served as a Managing Director at Citigroup, a global financial services firm, and earlier in his career served various operating, finance and accounting roles in both public accounting and in the banking industry. Mr. Dowling graduated from University of California, Los Angeles in Economics and is a certified public accountant.

Lysosomal Therapeutics, Inc.

KEES BEEN

Chief Executive Officer

Kees is CEO of Lysosomal Therapeutics, Inc. (LTI), a biotech company focused on probing the lysosomal enzyme system for new drug targets in neurodegenerative diseases. Specifically, it is leveraging the genetic link between Gaucher's and Parkinson's disease (PD) to develop compounds that enhance the lysosomal glucocerebrosidase enzyme activity as an entirely new and breakthrough class of agents for the personalized and disease-modifying treatment in PD patients with the GBA mutation. The company is currently working toward an exit as part of its option-to-buy collaboration with Allergan. He was formerly CEO of EnVivo Pharmaceuticals (changed to FORUM Pharmaceuticals) for eight years working on cognition drugs for Alzheimer's and schizophrenia. He spent four years at Biogen, where he directed the Oncology Business Unit which was sold to Idec, and was head of Business Development.

Kees holds an MBA degree from INSEAD in France and graduated from the University of Agriculture in Holland, majoring in Molecular Biology and Process Engineering. Kees likes to spend his weekend mornings flying his single-engine airplane, exploring local airports in the New England area that offer brunch menus.

Yumanity Therapeutics

KENNETH RHODES

Chief Scientific Officer

Kenneth Rhodes, Ph.D., is chief scientific officer, Yumanity Therapeutics. Dr. Rhodes oversees the company's integrated discovery platforms in addition to its drug discovery research programs. Dr. Rhodes was previously vice president, neurology discovery at Biogen, where he led an organization focused on discovery and early development of protein and small molecule drugs in the neurology therapeutic area. Among the notable achievements of Dr. Rhodes' group were the advancement of aducanumab (BIIB037; a monoclonal antibody for the treatment of Alzheimer's disease, now in Phase III), opicinumab (BIIB033; a monoclonal antibody for myelin repair in multiple sclerosis, now in Phase II) and BIIB054 (a monoclonal antibody for the treatment of Parkinson's disease, now in Phase II) into human clinical trials. Dr. Rhodes has more than 25 years of biopharmaceutical R&D experience spanning Wyeth, J&J, Biogen and Yumanity. Dr. Rhodes is a longstanding member of the Children's Hospital Boston Technology Development Fund, evaluating investments in translational drug discovery and development emerging from Children's research programs. His career has seen a consistent commitment and focus on finding new therapies for patients suffering from neurodegenerative diseases.

Blackstone Life Sciences

KIRAN REDDY

Venture Partner

Kiran Reddy is a Venture Partner of Blackstone Life Sciences group, having joined Blackstone as part of its acquisition of Clarus in December of 2018. Mr. Reddy is CEO of Praxis Medicines.

Prior to Clarus, Mr. Reddy was at Biogen as part of the Corporate Strategy leadership team where he focused on sourcing new technologies and product opportunities to support the Company's growth via acquisitions, partnerships, and equity investments. Prior to Biogen, Mr. Reddy was an Associate Partner at Third Rock Ventures. He supported and managed various portfolio companies in addition to focusing on new company formation and new investments. He was part of the founding team and interim Chief Business Officer for SAGE Therapeutics through its IPO, and co-inventor of SAGE-547 the Phase 3 program for the rare epilepsy disorder refractory status epilepticus. Mr. Reddy was part of the team that launched Foundation Medicine, and he has served as a Board Observer for Alnara pharmaceuticals, Rhythm pharmaceuticals, and PanOptica pharmaceuticals. Before Third Rock Ventures, Mr. Reddy was a management consultant at the Lewin Group within in the biotechnology and pharmaceutical practice, and advised clients on clinical development and commercial strategy.

Mr. Reddy holds MD and MBA degrees from Georgetown University. He completed his internship in medicine and his neurology residency at Harvard/Massachusetts General Hospital and is a board certified neurologist. Mr. Reddy was previously a Howard Hughes science fellow, and has authored several peer-reviewed scientific papers in the field of neuroimmunology and neurodegenerative diseases.

Boehringer Ingelheim International GmbH

LAURA CORRADINI

Deputy Global Head BD&L, CNS

Dr. Laura Corradini received her degree in medicinal chemistry and technology, and qualified as Pharmacist at the University of Milan (Italy). Subsequently, she obtained her PhD in biotechnology at the same University.

Dr. Corradini worked for more than ten years in preclinical research at Schering-Plough Research and Development (R&D) and Pfizer R&D in the field of neuroscience and chronic pain, respectively. Since joining Boehringer Ingelheim (BI) in 2009, she has held several positions in R&D as CNS Pharmacologist for pain and ophthalmology. In 2015, Dr. Corradini joined the Business Development & Licensing team.

Dr. Corradini currently acts as Deputy Global Head of Business Development & Licensing CNS at BI. She is responsible for search and evaluation of partnering opportunities in the therapeutic area CNS and is chairing BI's cross-functional CNS Licensing Advisory Team.
The strategic partnering focus of Dr. Corradini and her team is novel therapeutic approaches to treating neuropsychiatric disorders.

M3 Biotechnology, Inc.

LEEN KAWAS

President & CEO

Leen Kawas has led the company in business and financial growth through two oversubscribed financing rounds. The funds raised will support and accelerate growth of the company and take the lead candidate through the early stages of human testing.

For her leadership and accomplishments at M3 Biotechnology, Leen has won many awards and recognitions including: 40 under 40 in Life Science Leader (2017), PharmaVOICE 100 honoree (2017), Entrepreneur of the Year award from the Association of Washington Business (2016), was selected as one of EY's Winning Women Entrepreneur (2016), 40 under 40 award from the Puget Sound Business Journal (2016), Entrepreneur of the Year Finalist for EY (2016) and a Young Entrepreneur of the Year Finalist for GeekWire (2016). She was named one of Seattle's Most Influential People by Seattle Magazine (2015) and one of the Women to Watch in Life Sciences by the Washington Biotechnology and Biomedical Association (2015). As a company, M3 Biotechnology was also just named as one of Seattle's 10 hottest startups by GeekWire in 2016.

She also serves on multiple boards, including the Washington Governor's Life Science Advisory Board, the Scientific Review Board for the Alzheimer's Drug Discovery Foundation and the Alzheimer's Association-Washington Chapter Board, She also co-chairs the International Alzheimer's Association Business Consortium.

Stalicla SA

LYNN DURHAM

Founder & CEO

Her life long involvement with the Autism community has brought her to develop a unique patient centric vision of Drug Development to address the unmet medical needs of current and future patients with Autism. She has developed a first in class patient centered ASD phenotyping algorithm by partnering with Information Data Scientists.

She then launched STALICLA SA in May 2017 in order to kick-start personalized medicine in ASD. Fostering on her networks within the Neuroscience research community and pharmaceutical industry, she aims to rapidly position STALICLA SA as a disruptive industry challenger. She is leading STALICLA's ongoing IP strategy with world class IP councils in order to support STALICLA's fast paced growth objectives. Lynn lives in Geneva, Switzerland. She has extensive experience in Business development and has worked in the past for the World Economic forum, venture capital start-up promoting initiatives in the Lemanic area of Switzerland and more recently as a neuroscience and oncology focused medical fundraiser. In this role, she has secured extensive financing resource for major translational initiatives.

Lynn holds a master's degree in economic history and another in corporate communication. She is currently finalizing a post graduate degree in Drug Discovery and Clinical Development at the Faculty of medicine of the University of Geneva.

Bay City Capital, LLC

MANUEL LÓPEZ-FIGUEROA

Managing Director

Manuel López-Figueroa, PhD, is a Managing Director at Bay City Capital and has been with the firm since 2001. He specializes in evaluating investment opportunities with an emphasis on CNS. In addition, Dr. López is the Scientific Liaison for the Pritzker Neuropsychiatric Disorders Research Consortium, a collaborative research enterprise comprised of a group of leaders in psychiatry, neuroscience, and genetics from Stanford University, University of Michigan, Cornell University, and the Universities of California at Davis and Irvine. The consortium aims to discover the neurobiological and genetic determinants of mood disorders and schizophrenia with the goal to develop novel diagnostics and therapeutics. Dr. López is responsible for planning and directing all aspects of the consortium including strategy, R&D, legal (IP & contracts) and financial, to facilitate the commercialization of discoveries to fund additional research. Dr. López has over 15 years of experience in the field of neuroscience, has won numerous awards during his academic research career, and has published extensively. He completed post-doctoral work at the University of Michigan and at the University of Copenhagen, Denmark. Dr. López received a PhD in Medicine and Surgery, and a MS in Molecular and Cell Biology from the Universities of Las Palmas and La Laguna, Spain, respectively.

Broadview Ventures, Inc.

MARIA BERKMAN

Director and Head of the MedTech practice

Maria Berkman, MD, MBA, is a Director, and Head of the MedTech practice at Broadview Ventures.

Maria shares responsibility for all aspects of Broadview's investment activity, from identification and screening of new opportunities, through due diligence, negotiation of deal structure, and portfolio company board involvement.

Prior to joining Broadview Ventures, Maria was a management consultant at Monitor Group (now Monitor Deloitte), where she specialized in life sciences with a focus on corporate, franchise, and asset-level commercialization strategy and competitive strategic planning for a broad range of BioPharma and MedTech clients. Prior to joining Monitor Group, Maria trained within the Partners HealthCare System at Newton Wellesley Hospital in General Surgery. Maria earned an MD from the UCLA School of Medicine, graduating Alpha Omega Alpha with a research focus in cardiothoracic and trauma surgery, and earned an MBA from the Anderson School of Management at UCLA.

Maria serves on the boards of 480 Biomedical, Adient, BioKier, Cardialen, FineHeart, Vascular Graft Solutions, Vectorious, and Zumbro Discovery, and previously served on the boards of Apama (acquired by Boston Scientific) and Capricor (NASD:CAPR).

In addition to her role at Broadview Ventures, Maria contributes time as a SBIR/STTR grant reviewer for the National Science Foundation and is a Strategic Advisory Board Member for the RAD BioMed Accelerator in Tel Aviv, Israel.

Bioasis Technologies, Inc.

MARK DAY

President & CEO

Mark Day, Ph.D. is a director and the president and chief executive officer at Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF). Dr. Day also serves as adjunct associate professor at Yale University. Dr. Day has more than 20 years of experience working in the industry. He has developed business plans for Alexion Pharmaceuticals, Wyeth, Glaxo Smith Kline (GSK) and Bristol-Myers Squibb (BMS) in multiple functional areas ranging from the development of external research discovery engines and global scouting strategies to the creation of internal venture/investment funds.

Dr. Day has established and managed more than 20 collaborations, mergers and acquisitions and licensing deals in research and development (R&D) and business development. Dr. Day was head of translational medicine neuroscience at Wyeth and was the co-chair of the early development team. At Abbott, he was responsible for translational imaging and biomarkers across the R&D portfolios. At BMS, Dr. Day was instrumental in the acquisition of iPierian and he has developed strategies that can shorten evaluation periods by several months, leading to early decisions regarding the advancement or early termination of the evaluative processes.

Dr. Day previously served as head, CNS virtual discovery, at Purdue Pharma. Prior to joining Purdue Pharma, he served as executive director, head of external research and scouting, at Alexion Pharmaceuticals, Inc. He is widely recognized for his expertise and success in the recognition, evaluation and development of pipeline acquisition and collaboration targets across several therapeutic areas. Dr. Day has presented his evaluations and formal recommendations at the highest corporate levels and has also participated in the resulting deal negotiations, leading to several high-profile acquisitions and collaborations.

Biogen

MICHAEL EHLERS

Executive Vice President

Michael Ehlers is Executive Vice President for Research & Development at Biogen, one of the largest and most successful biotechnology companies in the world. Dr. Ehlers grew up rural Nebraska and earned his bachelor's degree in chemistry from Caltech. He holds M.D. and Ph.D. degrees from the Johns Hopkins University School of Medicine. Prior to joining Biogen in 2016, Dr. Ehlers was Senior Vice President for BioTherapeutics and Chief Scientific Officer for Neuroscience at Pfizer where he led the transformation of the Neuroscience and Rare Disease portfolios at Pfizer successfully bringing 22 compounds into the clinic, as well as directing global activities in biologics design, synthesis, and production, and steering a network of academic collaborations focused on immunology and oncology. Before entering his industry career in 2010, Dr. Ehlers was the George Barth Geller Professor of Neurobiology and an Investigator of the Howard Hughes Medical Institute at Duke University Medical Center, where he pioneered studies on neuronal organelles and the trafficking of neurotransmitter receptors. Dr. Ehlers' current research focuses on the interface between neuronal cell biology, the plasticity of neural circuits, and neurological disease. At Biogen, Dr. Ehlers directs global research and development including discovery sciences, drug design, translational medicine, and clinical development, with a focus on neurological diseases. He has advanced 12 novel clinical candidate compounds and oversaw the approval of SPINRAZAä(nusinersin), the first drug approved for spinal muscular atrophy. He is the recipient of numerous awards including the 2003 Eppendorf & Science Prize in Neurobiology, the 2007 John J. Abel Award in Pharmacology, the 2007 Society for Neuroscience Young Investigator Award, an NIMH MERIT Award, and the 2009 National Alliance for Schizophrenia and Depression Distinguished Investigator Award. He received the 2008 Breakthrough Research Award of the North Carolina Biotechnology Center given to a single scientist in North Carolina, and the 2016 Biomedical Research Award of the Massachusetts Medical Society given to a single business leader in New England. In 2013 he became the 11th recipient of the Thudichum Medal of the Biochemical Society of the United Kingdom an award inaugurated in 1974 to honor eminent scientists who have made outstanding contributions to neurochemistry and related subjects, whose recipients include two Nobel laureates. Dr. Ehlers has authored over 100 scientific papers, has served on the Editorial Boards of Annual Reviews in Medicine, Annual Reviews in Pharmacology and Toxicology, the Journal of Neuroscience, the Journal of Biological Chemistry, and Molecular and Cellular Neuroscience, and sat on advisory committees of the National Institutes of Health. He is a member of the American Society for Cell Biology Governing Council, the Janelia Research Institute Advisory Committee, and the McKnight Endowment Fund for Neuroscience Board of Directors. He serves on the advisory boards of several private foundations, and advises major pharmaceutical, venture, academic, government, and biotech organizations..

Valor Management SA

MICHAEL FARLEY

Director

Michael founded Valor Management in 2002, a business advisory servicing life science companies and investors in global markets. Prior to Valor, Michael managed technology and investment programs for the Canadian Foreign Affairs Department. He holds a PhD in the Philosophy of Science from the Université de Montréal (1986). Michael is fluent in several languages.

Metys Pharmaceuticals AG

MICHAEL SCHERZ

Founder & CEO

Michael Scherz, PhD is the founder and chief executive officer of Metys Pharmaceuticals AG. The company is developing MP-101, a non-sedating, orally-active allosteric modulator of brain and spinal glutamate signaling, for the management of neuropathic pain. Dr. Scherz is a drug development and discovery specialist, with more than 25 years' experience in central nervous system, cardiac, and immunological medicinal chemistry, pharmacology and drug development. Dr. Scherz holds a PhD in synthetic-medicinal chemistry from the University of Oregon for his work on the design and synthesis of novel NMDA-type glutamate-gated ion channel blockers.

During his post-doctoral training at F. Hoffman-La Roche in Basel, he elaborated novel glycine-site modulators of NMDA receptors. At Procter & Gamble Pharmaceuticals in Cincinnati he worked on voltage-gated potassium channel pharmacology and led the cardiac research department there. He joined the drug discovery management team at Actelion Pharmaceuticals in Allschwil, Switzerland, working on urotensin II receptor antagonists, orexin receptor antagonists, sphingosine-1-phosphate receptor agonists, and calcium channel blockers. He assumed the responsibilities of global development team leader for several preclinical, Phase 1, Phase 2 and pre-Phase 3 drug candidates. Dr. Scherz holds a deep respect and admiration for the drug discovery sciences and enjoys the challenge of positioning promising new drugs into the available therapeutic armamentarium, to plan their clinical development

BrainScope Company, Inc.

MICHAEL SINGER

Chief Executive Officer

Michael Singer has over 25 years of executive leadership with significant operating, healthcare and financial experience.

As CEO of BrainScope, Michael has guided the company from technology development, clinical studies, product validation, Intellectual Property creation, organizational build, and multiple regulatory clearances to commercial launch of the first FDA-cleared medical device for assessment of the full spectrum of brain injury, including concussion. Michael also secured significant equity investment and research funding through government and military research contracts.

Before Michael joined BrainScope, he was President of Revolution Health Investments, where he managed its sale to Everyday Health. He was previously the Chief Financial Officer, Executive Vice President of Corporate Development for Data Critical Corporation, a Seattle-based venture-backed medical device company. At Data Critical he was responsible for facilitating the company's IPO and eventually led the sale of Data Critical to General Electric (GE). He has also worked as an executive at Microsoft Corporation responsible for developing small business and healthcare strategies. For a decade Michael was a healthcare investment banker and M&A generalist for Wolfensohn & Co., Alex. Brown and Montgomery Securities in New York and San Francisco. He started his career at Union Bank of Switzerland in Zurich.

Michael has served on the Board of Directors of Exact Sciences Corporation (molecular diagnostics), MedEfficiency (medical devices, sold to Derma Sciences), SparkPeople (consumer health), One Reel (entertainment), and Data Critical Corporation (medical devices, sold to GE), and currently serves on the Advisory Board of the Maxwell School of Citizenship and Public Affairs. He holds a Ph.D. from the London School of Economics.

AbbVie, Inc.

MURALI GOPALAKRISHNAN

Head of Search & Evaluation - Neuroscience, Corporate Strategy Office

Murali joined Abbott/AbbVie in 1993 and subsequently held various positions of increasing responsibility leading research teams across therapeutic areas in neuroscience, pain, urology and nephrology, and advancing multiple clinical candidates. He has extensively published in scientific journals and was inducted to the AbbVie's Volwiler Research Society.

From 2009-2013, Murali took on the role as Head of the, then newly, formed Global External Research group, leading a team focused on developing external innovation strategies, and enabling the identification, scientific diligence and establishment of external collaborations around emerging science, targets, technologies and preclinical assets. He was also responsible for the leadership of AbbVie China R&D Center in Shanghai since its inception in 2009 and subsequently led the Renal Discovery Therapeutic Area across Shanghai and Chicago sites, and via a network of academic partnerships.

Since 2015, he has taken on a leadership position within AbbVie's Search & Evaluation team, with responsibilities for accessing and advancing opportunities in the Neuroscience Therapeutic area. He is currently Head of Search & Evaluation - Neuroscience, within the Corporate Strategy Office at AbbVie.

Murali obtained his undergraduate training in Pharmacy from Banaras Hindu University, India and a PhD in pharmacology from the School of Pharmacy, SUNY at Buffalo, New York. He completed his post-doctoral training in molecular biology at the Baylor College of Medicine, Houston, Texas and has an MBA degree from the Lake Forest Graduate School of Management, Illinois.

Stifel Financial Corp.

PAUL MATTEIS

Biotechnology Analyst

Paul Matteis joined Stifel in 2018. Based out of the Boston office, Mr. Matteis is a Managing Director, Senior Analyst, and Co-Head of the Biotech Research Team.

Mr. Matteis was previously a Senior Biotechnology Analyst covering small-cap and mid-cap companies at Leerink, with a focus on neuroscience and the central nervous system. He was named a "Rising Star" by Institutional Investor in both 2015 and 2016, as part of the publication's All-America Research Team rankings. Before starting at Leerink in 2012, Mr. Matteis was a Research Assistant at the Harvard Division of Sleep Medicine at Brigham & Women's Hospital in Boston.

He attended Skidmore College in New York, where he studied Psychology and Pre-Medical Sciences, and graduated Phi Beta Kappa.

UCB Pharma

PIERANDREA MUGLIA

Head, Neurology New Patient Value Mission

Pierandrea Muglia, M.D., is at UCB since 2012, initially as Vice President and Head of Neurology Discovery Medicine leading the early clinical development and translational medicine strategy for the neurology portfolio, and now heading the Neurology New Patient Value Mission that oversees the organic and inorganic growth for the neurology portfolio at UCB. Before joining UCB, Dr. Muglia was CMO and co-founder of Saniona S/A, a biotech, spin-off from NeuroSearch where Dr Muglia lead the clinical development activities for the CNS portfolio for three years. Dr Muglia started his Pharma career at GSK in 2003 in the Psychiatry early development organization, designing proof of concept studies for a number of psychiatric indications. While at GSK Dr. Muglia, established large scale genetics research networks that led to the identification of the first established genetic risk factors for bipolar disorder, schizophrenia and nicotine dependence.

Dr. Muglia is author of over 100 publications in the area of neuropsychopharmacology, drug development, genetics and biological psychiatry. He is co-founder and board member of Italian Autism Network, a not-for-profit organization devoted to the investigation of the biological factors involved in the etiology of autism spectrum disorders. Dr. Muglia received his M.D. and specialty training in child neurology and psychiatry in Italy followed by a post-doctorate and an independent academic research as Assistant Professor at the University of Toronto, in the Department of Psychiatry.

H.C. Wainwright & Co., LLC

RAGHURAM SELVARAJU

Managing Director and Senior Healthcare Equity Research Analyst

Raghuram "Ram" Selvaraju is currently a Senior Healthcare Equity Research Analyst and Managing Director at H.C. Wainwright & Co., LLC, a leading healthcare-focused investment bank headquartered in New York City, where he has worked since mid-2015. He was previously a Senior Healthcare Equity Research Analyst and Managing Director at MLV & Co., LLC, which is now part of B. Riley/FBR. Prior to MLV, Dr. Selvaraju was Head of Healthcare Equity Research at Aegis Capital Corp. for roughly three years. Before joining Aegis, Dr. Selvaraju held positions as Senior Biotechnology Analyst at Morgan Joseph TriArtisan LLC and Noble Financial Group, as well as an appointment as Senior Vice President and Head of Healthcare Equity Research at Hapoalim Securities U.S.A., Inc., the New York-based broker/dealer subsidiary of Bank Hapoalim B.M., Israel's largest financial services group. He possesses a total of nearly two decades' worth of experience in the biotech and pharmaceutical sectors.

Dr. Selvaraju started his career in 2000 at the Serono Pharmaceutical Research Institute in Geneva, Switzerland, the applied research arm of Serono, Europe's largest biopharmaceutical firm at the time. During his time in drug development, he was a highly decorated young scientist, winning both corporate awards and broader recognition within the academic community. Dr. Selvaraju began his equity research analyst career on Wall Street in 2005 at Rodman & Renshaw. Dr. Selvaraju has been quoted in such publications as The Wall Street Journal, MSN Money, Barron's, Bloomberg Businessweek, Reuters, Streetwise Reports, BioWorld Today, The Pink Sheet, PharmaVoice, The Wall Street Transcript and BioCentury, and has also made multiple appearances on Bloomberg TV, Bloomberg Radio and CNBC, discussing biotech and pharmaceuticals stocks and the outlook for the healthcare industry. He has been ranked by StarMine based on earnings estimate accuracy and his team at Rodman & Renshaw was ranked #1 in The Wall Street Journal's annual "Best On The Street" survey among biotechnology analysts based on overall portfolio return. He has published highly-regarded sector reports on Alzheimer's disease, multiple sclerosis, stroke, orphan neurological disorders, and the most comprehensive Wall Street research produced to date on U.S. healthcare reform policy. Among his academic qualifications, Dr. Selvaraju holds a Bachelor of Science in Biological Sciences and Technical Writing from Carnegie Mellon University, a Doctorate in Cell Biology and Neuroscience and a Master's of Science in molecular biology from the University of Geneva in Switzerland and an M.B.A. from Cornell University's accelerated one-year program for scientists and engineers. Dr. Selvaraju has also published articles in leading peer-reviewed journals, presented research at various scientific conferences, and is a co-inventor on several drug development patents.

Brainstorm Cell Therapeutics, Inc.

RALPH KERN

COO & CMO

Ralph Kern MD MHSc is Chief Operating Officer and Chief Medical Officer at BrainStorm Cell Therapeutics. He completed neurology training at McGill University, practiced neuromuscular neurology at Mount Sinai Hospital in Toronto and was head of the post graduate academic neurology program at the University of Toronto. He completed further post graduate training in heath administration at the Institute for Health Policy Management and Evaluation at the University of Toronto. Ralph received his MD degree from Queen's University, is board certified in neurology and neuromuscular disease, and is a member of the Royal College of Physicians and Surgeons of Canada.

Ralph joined Genzyme in 2006 where he led Genzyme medical activities in Canada and moved to Boston where he led Fabrazyme global commercial activities as general manager in the personalized genetic health business. Subsequently he joined Novartis in 2011, where he assumed the role of VP and head of the neuroscience medical unit, leading the global launch of Gilenya. Subsequently Ralph moved to Biogen in 2015 where he assumed the role of SVP and head of the worldwide medical organization- his team launched Zinbryta in MS and Spinraza in SMA and developed the medical and scientific strategy for MS, SMA and Alzheimer's disease.

Canopy Health, a Canopy Growth Corporation company

RAMI BATAL

Vice President Medical Research

Dr. Rami Batal is currently the Vice-President Medical Research of Canopy Growth, where he is responsible for setting up and managing clinical development programs in CNS (nervous system disorders: including psychiatric, neurological and pain-related). Prior, Rami was Vice-President Business Development at Purdue Canada, a member of the Executive Leadership Team, and a contributor to the global business development effort. At Purdue Canada, Rami led the expansion of the product portfolio beyond opioid analgesics into other CNS areas, including other pain platforms, as well as cancer supportive care. Prior, Rami worked extensively with big pharma, predominantly Johnson & Johnson/Janssen, in North America and Europe on enriching their external pipelines by acquiring novel medicines, with a particular focus in CNS. Dr. Batal holds a doctorate in Experimental Medicine from McGill University, and an MBA. He is a Pharmacist who continues to practice intermittently, and accordingly maintains patient proximity and intimate familiarity with healthcare delivery, in community settings.

Serina Therapeutics, Inc.

RANDALL MOREADITH

President & CEO

Randall joined Serina Therapeutics in September 2010 as President and Chief Executive Officer. Prior to joining Serina, Dr. Moreadith, 64, was Chief Development Officer at Nektar Therapeutics where he built a clinical and drug development program that successfully advanced the company's PEGylated small molecule drugs into the clinic, including the launch of NKTR-102 into four clinical indications (ovarian, breast, cervical and colorectal cancer) and the out-licensing efforts for NKTR-118 (approved product now known as Movantik®, Astra Zeneca and Daiichi Sankyo). Dr. Moreadith was co-Founder, President and Chief Operating Officer of ThromboGenics Ltd. (now Oxurion), a leader in the field of drug development for back of the eye disorders. During his tenure at ThromboGenics, the company advanced four biologics into mid-stage development, and one product was later approved (Ocriplasmin™). Dr. Moreadith began his career in the pharmaceutical industry as Principal Medical Officer of Quintiles, Inc., the world's leading pharmaceutical services organization, where he led the Cardiovascular Therapeutics Group.

Dr. Moreadith has published more than 50 scientific papers and multiple book chapters, is an inventor on multiple patents, and has received numerous awards for his achievements. He received his MD from Duke University and is trained clinically in Internal Medicine and Cardiovascular Diseases. He received his PhD from Johns Hopkins University, and following his Fellowship in Cardiology at Duke University he was a Howard Hughes Medical Institute Fellow in Genetics at Harvard Medical School. Dr. Moreadith was a member of the faculty of the University of Texas Southwestern Medical Center, and an Established Investigator of the American Heart Association.

Vitality Biopharma, Inc.

ROBERT BROOKE

Chief Executive Officer

Robert Brooke is the CEO and co-founder of Vitality Biopharma, a drug development company dedicated to unlocking the power of cannabinoids for treatment of serious neurological and inflammatory conditions. Previously, he was the founder of a cancer drug development company that is now known as Iovance Biotherapeutics, Inc. (NASDAQ: IOVA). Mr. Brooke is also a co-founder and serves on a limited part-time basis as the CEO of Intervene Immune, Inc. From 2004 to 2008, he was an analyst with Bristol Capital Advisors, LLC, investment manager to Bristol Investment Fund, Ltd. During this period, Bristol financed over 60 public healthcare and life science companies, and was listed by The PIPEs Report in 2005 as being the most active investor in private placements by public biotechnology companies.

Mr. Brooke has a BS. in Electrical Engineering from Georgia Tech and an MS in Biomedical Engineering from UCLA

Novaremed AG

SARA MANGIALAIO

CMO and Head of R&D

After completing her medical degree at the University of Milan (Italy), Dr. Mangialaio obtained PhD in Immunology at the University of Strasbourg (France) and a Master in Project Management at the George Washington University (USA).

Dr. Mangialaio joined Novaremed in 2017, as Chief Medical Officer and Head of R&D. She has more than 18 years of experience in the pharmaceutical industry. She was previously Therapeutic Area Head, Clinical Program Head and Clinical Science Operation Unit Head at Actelion, where she spent more than 8 years working in multiple indications, including insomnia and psychiatric disorders. Prior to this, she had worked for 9 years at Novartis, where she covered projects spanning from target selection to phase IV. At Novartis and Actelion, she had leadership of clinical, regulatory, diagnostic and biomarker cross-functional global teams and task forces. In addition, she was responsible for successful submissions and interactions with Regulatory Authorities, including drug approval, label negotiation and orphan drug designation. She has long standing experience in people and resource management, as well as in planning and execution of clinical trials.

Tonix Pharmaceuticals Holding Corp.

SETH LEDERMAN

Chief Executive Officer

Seth Lederman is a physician, scientist, founder and executive officer of innovative biopharmaceuticals companies. Prior to founding Tonix, among the companies Dr. Lederman founded was Targent Pharmaceuticals, which developed late-stage oncology drugs, including pure-isomer levofolinic acid (levoleucovorin). Targent's assets were sold to Spectrum Pharmaceuticals, which marketed levoleucovorin as Fusilev® for advanced colorectal cancer, where it gained significant market acceptance.

Dr. Lederman served as an Associate Professor at Columbia University from 1996 until April 13, 2017. He joined the faculty of Columbia University's College of Physicians and Surgeons in 1985, became Assistant Professor of Medicine in 1988, and Associate Professor with tenure in 1996 and Director of the Laboratory of Molecular Immunology in 1997. From 1988 to 2002, Dr. Lederman directed basic science research at Columbia in molecular immunology, infectious diseases and the development of therapeutics for autoimmune diseases. Dr. Lederman is author of numerous scientific articles, and inventor of technologies recognized by a number of issued patents. His fundamental work on the CD40-Ligand (CD154) elucidated the molecular basis of T cell helper function and has led to the development of therapeutic candidates for autoimmune diseases and organ transplant rejection in collaboration with Biogen and UCB. The successful defense of his CD154 patents has led to important precedents in defining the relationship of therapeutics and molecular targets. In collaboration with Prof. David Baltimore (then at Rockefeller University and later MIT), Dr. Lederman identified and functionally characterized the CD40 signaling molecule, TRAF-3. His early work on HIV contributed to the understanding of how the V3 loop of HIV gp120 was involved in fusion with CD4 cell membranes, an early and essential event in viral entry and infection. In addition to his research, Dr. Lederman served as attending physician in the Edward Daniels Arthritis and Autoimmunity Clinic on the Medical Service at Columbia Presbyterian Hospital from 1988-1996.

Dr. Lederman earned an AB from Princeton in Chemistry cum laude in 1979 and an MD from Columbia University's College of Physicians and Surgeons in 1983. Dr. Lederman trained in internal medicine and rheumatology at Columbia's Presbyterian Hospital. He was an NIH Physician-Scientist 1985-1990 at Columbia.

BridgeBio, LLC

SHAFIQUE VIRANI

CEO in Residence

Shafique Virani is currently CEO in Residence at BridgeBio, LLC and CEO of Navire Pharma & CoA Therapeutics based in Palo Alto, CA. Until June 2017, he was Vice President, Global Head of Neuroscience, Ophthalmology & Rare disease (NORD) Roche Partnering. Shafique's responsibilities in this role encompassed all partnering activities within Roche's NORD franchise, from academic collaborations to licensing and acquisitions. Shafique joined Roche in 2004 and served various roles within medical affairs, marketing and business development in the UK, USA and Switzerland until 2012, when he transitioned to South San Francisco. Shafique is trained as a neurosurgeon in Cambridge, UK and Boston, USA and holds the Fellowship of the Royal College of Surgeons of England

CBT Advisors

STEVEN DICKMAN

Chief Executive Officer

CBT Advisors CEO Steve Dickman has worked in the biotechnology and venture capital industries for twenty years. He founded CBT Advisors in 2003 after a four-year stint as a venture capitalist with TVM Capital, where his investments included Sirna Therapeutics, acquired in 2006 by Merck for $1.1 billion, and bluebird bio, which went public on Nasdaq (BLUE) in 2013 and had a $6.8 billion valuation in November, 2017. His firm CBT Advisors has served nearly three hundred clients, including both public and private companies. Steve publishes from time to time on Forbes and Boston Biotech Watch.

CBT Advisors works on analysis and storytelling in all areas of life sciences including drug discovery and clinical development, molecular diagnostics, research tools and software and digital health. CBT Advisors pursues projects of four basic types:

- Drafting of prospectus text for later-stage companies
- Story and pitch development for earlier-stage companies including slide decks, business plans, market analysis and competitive positioning.
- Strategic reviews of private biotech and life sciences companies. On behalf of management teams and investors, we apply our understanding and insight into the positioning and fund-raising needs of VC-backed and angel-backed companies in order to drive changes in strategy, awareness of competitors, improvements in positioning and adjustment of goals and milestones.
- Company workshops to prepare for upcoming milestones and value inflection points

CBT Advisors' IPO clients, including Homology Medicines, Avrobio, Forty-Seven, NuCana, ArgenX and CRISPR Therapeutics, have had thirty-three Nasdaq IPOs, two EuroNext IPOs, one NASDAQ Stockholm IPO and seven reverse mergers. Altogether, these clients have raised more than $2.5 billion. Our private company clients, including BioNTech, Crescendo Biologics and MiNA Therapeutics, have gone on to other significant transactions or milestones.

Canaccord Genuity LLC

SUMANT KULKARNI

Managing Director, Biotechnology Equity Research

Sumant Kulkarni joined Canaccord Genuity in May 2017 as a New York-based Managing Director covering Biotechnology stocks. His initial research focus is on biotech companies within the central nervous system (CNS) space. Prior to that, Sumant was at Bank of America-Merrill Lynch where he covered biopharmaceutical stocks since 2005 as part of a top Institutional Investor-ranked team, and was most recently a director leading that firm's Specialty Pharmaceuticals franchise. He started his career on the sell-side covering the Life Science Services sector at Jefferies.

Sumant's background includes an MBA, an MS in chemical engineering and academic research in biomedical engineering (with a focus in oncology and cardiology) from The Ohio State University, and a bachelor's degree in chemical engineering from Bangalore University, India.

Cognition Therapeutics, Inc.

SUSAN CATALANO

Founder & CSO

Dr. Catalano is the founder of Cognition Therapeutics and architect of its proprietary and unique biological discovery platform that is based on unbiased phenotypic screens in the target cell population of mature primary neurons. Using her 15 years of industry experience, she and her team discovered and developed the company's drug candidate CT1812, currently in clinical testing for the treatment of patients with mild-to-moderate Alzheimer's disease. Prior to founding Cognition Therapeutics, Dr. Catalano was director of discovery biology for Acumen Pharmaceuticals, leading the team that discovered Acumen's lead candidates targeting Aβ oligomers. Earlier at Rigel, she led the team that pioneered the use of high content phenotypic screening to discover the Aurora kinase inhibitor R763. In scientific leadership roles within the neurophysiology and neuroimaging groups at Roche Palo Alto she led exploratory programs against targets involved in anxiety, depression and schizophrenia. Dr. Catalano received her Ph.D. from U.C. Irvine and postdoctoral training at U.C. Berkeley with Dr. Carla Shatz and at Caltech with Drs. Mary Kennedy and Scott Fraser studying the neurobiology of synaptic plasticity.

ADDRESS:
2223 Avenida de la Playa
Suite 206
La Jolla, CA 92037
United States

WEBSITE:
www.abreos.com

EMAIL:
busdev@abreosbio.com

PHONE:
+1 858 203 1169

COMPANY TYPE
Emerging

SECTOR:
Biotechnology
Pharmaceuticals

YEAR FOUNDED:
2013

Abreos Biosciences, Inc.

COMPANY PROFILE

Abreos is developing a new generation of integrated therapeutics solutions for autoimmune disease, neurology and oncology. Our approach centers on off-patent or repositioned biologic drugs combined with our proprietary Veritope™ drug monitoring platform. Our technology enables measurement and purification of biological molecules – such as monoclonal antibodies –and allows precision dosing for the individual patient. Personalized dosing improves tried and true mechanisms of action to deliver best-in-class efficacy, safety, and value-based cost efficiency with minimal clinical development risk.

MANAGEMENT TEAM

- Dr. Bradley Messmer - Chief Executive Officer
- Michael R. Williams - Chief Business Officer
- Helen Jenkins - Chief Operating Officer

PIPELINE

Our lead program, ABR-101, is a precision dosed anti-CD20 rituximab therapeutic for Multiple Sclerosis, a chronic autoimmune disease. Our integrated therapeutic approach will create a unique competitive entry into the quickly growing $5.9B MS biologic market. Furthermore, by repositioning a well-characterized biologic for a new FDA-approved indication, our development pathway will be decisively accelerated and de-risked while maintaining strong IP protection and regulatory exclusivity.

ABR-101 marks the initial entry in an extensive portfolio of integrated therapeutics.

Actinogen Medical Ltd.

ADDRESS:
Suite 901, Level 9, 109 Pitt Street
Sydney NSW 2000
Australia

WEBSITE:
www.actinogen.com.au

EMAIL:
info@actinogen.com.au

PHONE:
+61 2 8964 7401

COMPANY TYPE
Public

TICKER
[ASX: ACW]

SECTOR:
Biotechnology
Clinical Development
Pharmaceuticals/Clinical Research

YEAR FOUNDED:
2014

COMPANY PROFILE

Actinogen Medical (ASX:ACW) is an ASX-listed biotechnology company developing innovative treatments for Alzheimer's disease and the cognitive impairment associated with neurological diseases and metabolic diseases.

The Actinogen Medical management team and clinical and scientific advisory boards have extensive global clinical and drug development experience; including world-renowned Alzheimer's disease and dementia clinicians and researchers, and industry specialists in drug development, clinical trial management, biotechnology investment and business development. The company is supported by leading global and Australian institutional investors, including Biotechnology Value Fund LP (USA), Australian Ethical and Platinum Asset Management.

Actinogen Medical's lead drug candidate XanamemTM has been specifically designed to reduce production of excess cortisol in the brain. Chronically raised cortisol is a key risk factor for Alzheimer's disease, and the association between raised cortisol in the brain and cognitive decline has been well documented in the scientific literature. Drugs that reduce cortisol in the brain offer a promising new approach to slowing, or even preventing, the cognitive decline associated with Alzheimer's disease and a range of other neurological disorders associated with cognitive impairment.

Actinogen Medical has completed enrolment into XanADu; a Phase II double-blind, 12-week, randomised, placebo-controlled clinical study to assess the safety, tolerability and efficacy of 10mg once daily of Xanamem in subjects with mild dementia due to Alzheimer's disease. Actinogen Medical expects to announce the XanADu results in Q2 CY19.

Actinogen Medical has strong relationships with the global Alzheimer's disease community and is engaging with prospective biopharmaceutical partners through proactive business development and attendance at global partnering and clinical meetings.

For more information visit www.actinogen.com.au
For more information on the XanADu trial visit www.clinicaltrials.gov with identifier: NCT02727699

MANAGEMENT TEAM

Dr Geoffrey Brooke - Chairman
Dr George Morstyn - Non-Executive Director
Dr Bill Ketelbey - CEO and Managing Director

PIPELINE

In May and July 2018, an institutional placement and share purchase plan, respectively, raised a total of $16.5m from Biotechnology Value Fund LP (USA), Platinum Asset Management and Australian Ethical. The funds raised are being used to further drive the development of Xanamem including by undertaking a target occupancy study, a dose escalation safety study, and additional standard pre-clinical (animal) studies. This suite of studies will enhance the dataset in Alzheimer's disease and consolidate the Xanamem development plan in preparation for Phase III clinical development.

Xanamem's mechanism of action through the inhibition of cortisol, offers a broad platform of additional disease applications for which the drug could be developed. Additional indications beyond Alzheimer's disease are being investigated to further expand the market opportunities of Xanamem.



ADDRESS:
Alkerstraat 28
3570 Alken
Belgium

WEBSITE:
www.aneurotech.com

EMAIL:
erik.buntinx@aneurotech.com

PHONE:
+32 (0) 473 861 079

COMPANY TYPE
Emerging

SECTOR:
Neuroscience
Pharmaceuticals/Licensing

YEAR FOUNDED:
2017

ANeuroTech

COMPANY PROFILE

ANT01, a Phase IIa proprietary small molecule in the Prevention of Alzheimer Disease in well defined patients, is oriented to prevent in the US only at least 100.000 new AD cases per year by treatment of 1M patients life time. After 5 years of planned launch in 2030 and with a peak sales of 10B, this will save US healthcare costs by at least 50B giving ANT01 a very attractive value proposition.

Up till date, via clinical case studies, we were able to demonstrate that short term intervention with ANT01 led to a clinical relevant diminishment of the identified clinical risk factors for the development of Alzheimer Disease.

Objectives of ANT' 2019-2022 Business Plan are:
Further Development & Validation of ANT's Marker in Prevention of Alzheimer Disease (Milestone 1)
Proof of Concept Study in Prevention of Alzheimer Disease based on ANT' Marker (Milestone 2)
Phase IIA Study with ANT' Marker on ANT01 in Prevention of Alzheimer Disease (Milestone 3)

The Proceeds required for these milestones in a Series A investment round will add up to 50 M USD i.e.:
MS1: 5 M USD (tranche 1)
MS2: 15 M USD (tranche 2)
MS3: 30 M USD (tranche 3)

MANAGEMENT TEAM

As an emerging pharmaceutical development company, ANeuroTech is led by his founder and inventor Dr. Erik Buntinx, an experienced Chief Executive Officer with a demonstrated history of working in the pharmaceuticals industry. Skilled in Research, Management, Strategic Planning, Leadership, and Public Speaking. Strong business development professional with a Doctor of Medicine (MD) focused in Psychiatry Residency Program from Maastricht University School of Business and Economics.

PIPELINE



With an initial investment of $50 MLN, ANT will be able to deliver a virtually unencumbered Phase III ready asset in Prevention of Alzheimer Disease with a 10y+ lifecycle

ADDRESS:
100 Cummings Center Suite 451C
Beverly MA 01918
United States

WEBSITE:
www.atentiv.com

EMAIL:
information@atentiv.com

PHONE:
+1 508 954 0494

COMPANY TYPE
Private

SECTOR:
Behavioral Healthcare for Cognitive Disorders, beginning with ADHD and Early Alzheimer's
Digital Therapeutics

YEAR FOUNDED:
2011

ATENTIV, LLC

COMPANY PROFILE

ATENTIV is a commercial stage Neuro-Development company with a clinically validated platform of products and telehealth services for the durable remediation of childhood cognitive disorders without medication – beginning with ADHD followed by pre-MCI (Early Alzheimer's). It's proprietary platform of digital therapeutics activate the "rewiring" of the brain's attention circuitry to rapidly learn and improve targeted cognitive skills that were developmentally delayed during childhood or have become impaired. Our therapeutics lead to durable and significant improvements in academic performance, home behavior and life success, while reversing the negative symptoms of ADHD. Atentiv plans to extend its therapeutic platform to other cognitive dysfunctions such as pre-MCI, Autism, Anxiety, Depression, PTSD and TBI.

In eight rigorous clinical studies, relative to the $2.2B leader in the $10.2B ADHD stimulant market, ATENTIVmynd™ Games have demonstrated comparable efficacy yet significant superiority in sustainability and speed of action with no negative risks of side effects, stigma or abuse. Most importantly, students experienced sustained grade improvements in math fluency and reading comprehension and 30-40% improvement in test accuracy and homework completion. Training is home administered and remotely managed by professionals, in approximately twenty-four 20 minute sessions/day, in 3-5 sessions/week, spanning 5-8 weeks for a total of 8 hours.

Large Healthcare Network Providers faced with value-based payment contracts are now developing broad system-wide integration plans for ATENTIVmynd across tens to hundreds of thousands of patients. In November 2018, Atentiv announced its first Co-development and Supply Agreement with Children's Specialty Hospital of the RWJ/Barnabas Health System for product launch in Q4 2019. It is expected that aligned parties (payers, employers, pharma and technology cos) will also join this collaboration. Atentiv's leadership team has significant transformational success and deep commercial and medical domain experience.

MANAGEMENT TEAM

- Eric Gordon - Founder & CEO
- Don Apruzzese - Chief Commercial Officer
- Jonathan Rubin - Chief Medical Officer

PIPELINE

- Attention Child – Market Launch
- ADHD Child – Regulatory registration study in process
- Pre-MCI - Validation Studies
- Memory – Validation Studies
- ADHD Adult – Origination and Integration
- Autism - Origination



ADDRESS:
222 Berkeley Street
12th Floor
Boston MA 02116
United States

WEBSITE:
www.aztherapies.com

EMAIL:
info@aztherapies.com

PHONE:
+1 617 318 3411

COMPANY TYPE
Emerging

SECTOR:
Biotechnology
Neuroscience

YEAR FOUNDED:
2011

AZTherapies, Inc.

COMPANY PROFILE

AZTherapies, Inc. is a privately held advanced clinical stage pharmaceutical company developing breakthrough treatments for multiple neurodegeneration and neuroinflammation-related CNS diseases, including Alzheimer's (AD), ischemic stroke and ALS. Built around a broad IP portfolio exclusively licensed from Harvard Medical School and Massachusetts General Hospital, AZTherapies' initial product (ALZT-OP1) is a novel multi-action combination drug regimen to modify disease progression by slowing down or halting Alzheimer's disease early in its development. ALZT-OP1 addresses four mechanisms of action by treating the mechanisms associated with neural inflammation that triggers nerve death and progressive brain damage, and inhibiting amyloid-beta (Aβ) protein oligomerization and polymerization to aggregates that intoxicate neurons and interfere in their signaling as well as allowing the Aβ peptides to be removed from brain. The ALZT-OP1 program is currently enrolling patients in a Phase III study under a Special Protocol Assessment with the FDA.

The Company's second clinical stage product candidate (ALZT-PSCI) is an adjuvant treatment for post ischemic stroke cognitive impairment, or PSCI. Acting to both inhibit mast cells that release cytokines and toxins, and to activate the M2 phagocytic state of microglia cells that absorb toxins, AZLT-PSCI aims to treat neuroinflammation that exacerbates areas of brain injury post-stroke. The Company's IND for ALZT-PSCI has been accepted by the FDA, with planned enrollment of a 500 patient Phase II pivotal clinical trial across North America and Israel, which is planned for 2Q 2019.

The Company's second-generation AD therapy (ALZT-OP2) has been through IND enabling NGI, toxicity and interaction testing and analysis. ALZT-OP2 is a novel modified combination drug, dosed as a single inhaled capsule aimed at improving patient treatment compliance, and simplifying production and distribution. We expect ALZT-OP2 to be ready for human clinical trials in 1H of 2019.

Separately, the Company has agreed to work with Massachusetts General Hospital to investigate the effect of its platform of neuroinflammatory drugs in ALS mouse models.

MANAGEMENT TEAM

- David R. Elmaleh, PhD - Scientific Founder and Chairman
- Karen Reeves, MD - President and Chief Medical Officer
- Robert S. Warren - Chief Operating Officer and Chief Financial Officer
- David Brazier - Sr. Director, Clinical Operations
- Keith D. Greenfield - Director and EVP of Business Development
- Juan B. Gonzalez - Vice President of Quality and Technical Operations

PIPELINE

A novel program, shaping the future of Alzheimer's treatment

Our current programs for drug development and commercialization have the following foci: to neutralize the amyloid triggers of Alzheimer's disease (ALZT-OP1), to facilitate drug regimen dosing and compliance in persons that already experience some memory loss (ALZT-Patch), and to lessen the impact of potential damage already done by Alzheimer's disease (ALZT-QoL).

ADDRESS:
14 Water Street
Guilford, CT 06437
United States

WEBSITE:
www.bioasis.us

EMAIL:
Info@bioasis.us

PHONE:
+1 203 533 7082

COMPANY TYPE
Public

TICKER
[OTCQB:BIOAF]
[TSX.V: BTI]

SECTOR:
Biotechnology
Neuroscience

YEAR FOUNDED:
2007

Bioasis Technologies, Inc.

COMPANY PROFILE

Bioasis Technologies, Inc. is a biopharmaceutical company developing the xB³™ platform, a proprietary technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases.

The delivery of therapeutics across the BBB represents the final frontier in treating neurological disorders. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders. The xB³ platform technology is a non-invasive, multi-modal solution to the problem of transporting complex therapeutic molecules across the BBB. The xB³ platform has advantages over other BBB technologies in terms of payload flexibility and efficiency of delivery. The Company is also actively pursuing licensing and business development opportunities for the advancement of external neuroscience and oncology programs.

Bioasis maintains headquarters in Guilford, Conn., United States. Bioasis trades on the TSX Venture Exchange under the symbol "BTI" and on the OTCQB under the symbol "BIOAF." For more information about the company, please visit www.bioasis.us.

MANAGEMENT TEAM

- Mark Day, Ph.D. - Director, President and Chief Executive Officer
- Caroline Clairmont, Ph.D. - Senior Vice President, Research & Development Operations
- Mei Mei Tian, Ph.D. - Vice President, Head of External Research
- Catherine London - Executive Vice President, Head of Corporate Communications and Investor Relations

BlackThorn Therapeutics

ADDRESS:
780 Brannan Street
San Francisco, CA 94103
United States

WEBSITE:
www.blackthornrx.com

EMAIL:
info@blackthornrx.com

PHONE:
+1 415 548 5401

COMPANY TYPE
Private

SECTOR:
Biotechnology

YEAR FOUNDED:
2015

COMPANY PROFILE

BlackThorn Therapeutics is a privately-held, clinical-stage biopharmaceutical company based in San Francisco.

Our drug discovery and development approach builds upon recent advances and insights we have generated in understanding neurobehavioral disorders through a circuit-based approach vs. the historical categorical approach. By viewing neurobehavioral disorders in this new construct, we believe we can more successfully advance targeted therapeutics. We have a deep pipeline of best-in-class and first-in-class molecules targeting key neurobehavioral health needs.

The final element of our novel approach to central nervous system (CNS) therapeutics is the deep integration of advanced data science insights into our discovery and development processes. With advanced technologies in neuroinformatics, functional magnetic resonance imaging, gene-expression mapping, quantitative behavioral assessments, and digital biomarkers, we are re-envisioning CNS therapeutics to improve neurobehavioral health.

MANAGEMENT TEAM

- Paul L. Berns - Executive Chair
- Bill Martin, Ph.D - President and Chief Operating Officer
- Annette Madrid, M.D. - Chief Medical Officer

MILESTONES

- Expanded our board of directors
- Developed a robust pipeline of investigational therapeutics
- Advanced our lead compound into Phase 2a clinical testing and received Investigational New Drug (IND) approval for initiation of a second clinical indication
- Taken our second molecule from lead optimization to Phase 1 clinical trials
- Were named a 2017 Fierce 15 company by FierceBiotech
- Moved to a new facility in San Francisco's SOMA neighborhood to draw more deeply on the local science and technology talent

PIPELINE

BrainScope Company, Inc.

ADDRESS:
4350 East-West Hwy
Suite 1050, Bethesda, MD 20814
United States

WEBSITE:
www.brainscope.com

EMAIL:
Info@brainscope.com

PHONE:
+1 855 927 246 1

COMPANY TYPE
Private

SECTOR:
Biotechnology
Medical Device
Neuroscience

YEAR FOUNDED:
2006

COMPANY PROFILE

BrainScope is revolutionizing the rapid and objective assessment of brain-related conditions, starting with concussion and mild traumatic brain injury (mTBI). BrainScope's technology platform integrates databases of thousands of brainwave recordings with AI technology, multiple assessment capabilities, digitized miniaturized hardware and disposable sensors, all covered by an intellectual property portfolio of >100 issued and pending patents globally. BrainScope has received five FDA clearances and ISO 13485 Certification, and has 25 peer-reviewed publications on its technology.

The Company's first product, BrainScope One (cleared as Ahead 300), incorporates a multi-modal panel of non-invasive capabilities including EEG technology, and is the only FDA-cleared medical device that empowers clinicians to rapidly and objectively assess the full spectrum of concussion and mTBI at the point of care. BrainScope One is currently being used in practice by the U.S. military, ERs, urgent care and occupational health clinics, concussion clinics, universities, professional sports, and in pharmaceutical clinical trials.

BrainScope has raised private funding plus $32mm from 8 research contracts through its technology development partnership with the U.S. military. BrainScope was the recipient of the Frost & Sullivan 2017 Best Practices Award for New Product Innovation - TBI Assessment Solutions, a two-time winner of the GE-NFL Head Health Challenge, and received two nominations for the Prix Galien Best Medical Technology, regarded as the equivalent of the Nobel Prize for medical devices. The company is currently in discussions to leverage the technology platform to assess multiple neurological conditions outside of concussion/mTBI such as Alzheimer's/cognitive decline, depression, stroke and Parkinson's.

MANAGEMENT TEAM

- Michael E. Singer – Chief Executive Officer
- Laurie Silver – Chief Financial Officer
- Leslie S. Prichep, Ph.D. – Chief Scientific Officer
- David Elliot – Vice President, Marketing
- Miya R. Gray – Vice President, Customer Operations
- Rachel Walter – Vice President, Human Resources

PIPELINE



Brainstorm Cell Therapeutics, Inc.

ADDRESS:
1325 Avenue of Americas
New York, NY 10019
United States

WEBSITE:
www.brainstorm-cell.com

EMAIL:
info@brainstorm-cell.com

PHONE:
+1 201 488 0460

COMPANY TYPE
Public

TICKER:
[NASDAQ:BCLI]

SECTOR:
Biotechnology
Neuroscience

YEAR FOUNDED:
2000

COMPANY PROFILE

BrainStorm Cell Therapeutics (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as:

- Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease and Motor Neuron Disease)
- Multiple Sclerosis
- Parkinson's Disease
- Huntington's Disease

Our platform technology, NurOwn®, uses proprietary culture conditions to induce mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs) known to promote the survival of neurons. Our research efforts have shown that these MSC-NTF cells might be an effective tool for battling neurodegenerative diseases.

MANAGEMENT TEAM

- Chaim Lebovits - President and Chief Executive Officer
- Ralph Kern, M.D., MHSc - Chief Operating Officer and Chief Medical Officer
- Arturo Araya - Chief Commercial Officer
- Joseph Petroziello, BSc, MSc - VP of Scientific and Corporate Communications
- Susan E. Ward, Ph.D. - Head of Clinical Operations
- Eyal Rubin - EVP, Chief Financial Officer
- Uri Yablonka - EVP, Chief Business Officer
- Mary Kay Turner - VP of Patient Advocacy and Government Affairs
- Yael Gothelf, Ph.D. - VP Scientific and Regulatory Affairs
- Yossef Levy, Ph.D. - VP Cell Production
- Revital Aricha, Ph.D. - VP Research & Development
- Alex Burshtein, M.Sc. - Quality Assurance Manager

PIPELINE

Cantabio PHARMACEUTICALS

ADDRESS:
1250 Oakmead Pkwy
Sunnyvale, CA 94085-4037
United States

WEBSITE:
www.cantabio.com

EMAIL:
info@cantabio.com
ir@cantabio.com

PHONE:
+1 408 501 8893

COMPANY TYPE
Public

TICKER
[OTCMKTS: CTBO]

SECTOR:
Neurodegenerative Diseases

YEAR FOUNDED:
2009

Cantabio Pharmaceuticals, Inc.

COMPANY PROFILE

Cantabio Pharmaceuticals is a preclinical stage biotechnology company focusing on the research and development of disease modifying therapeutics candidates for Alzheimer's (AD), Parkinson's (PD) and related neurodegenerative diseases. Through its in-house drug discovery programs, Cantabio is targeting the reduction of protein aggregation and oxidative and glyoxal stress; major causes of AD and PD. Cantabio develops small molecule pharmacological chaperones, which act to stabilize the functional form of selected protein targets against their misfolding that occurs in disease conditions, when these proteins lose their function and/or become toxic. Cantabio is specifically developing on the following therapeutic programs: (1) CB101: small molecule pharmacological chaperones targeting the DJ-1 protein for PD; (2) CB201: engineered cell-penetrant DJ-1 protein for PD; (3) CB301: small molecule pharmacological chaperones targeting the Tau protein for AD.

MANAGEMENT TEAM

- Gergely Tóth, PhD, MBA - Founder, Chief Executive Officer
- Thomas Sawyer, MBA - Chief Operations Officer
- Simon Peace, MBA - Chief Financial Officer

PIPELINE

Therapeutic Program	Indication	Pre-clinical	Phase I
DJ-1 small molecule pharmacological chaperone	PD		
Cell penetrant engineered DJ-1	PD		
Tau small molecule pharmacological chaperone	AD		
Aβ small molecule pharmacological chaperone	AD		

ADDRESS:
44 Cook Street
Suite 100-71
Denver, CO 80206
United States

WEBSITE:
www.cerecin.com

EMAIL:
info@cerecin.com

PHONE:
+1 303 999 3700

COMPANY TYPE
Private

SECTOR:
Biotechnology
Medical Devices
Neuroscience
Pharmaceuticals

YEAR FOUNDED:
2001

Cerecin, Inc.

COMPANY PROFILE

Cerecin is a global healthcare company with almost 20 years of innovation and leadership in brain health.

At Cerecin we think differently. We develop novel evidence-based solutions that help people; pharmaceuticals, medical foods, diagnostics, medical devices and e-health products. These solutions target conditions ranging from memory impairment to some of the most devastating neurological diseases.

Cerecin is headquartered in Singapore and the USA, and our therapies are developed for persons around the world

MANAGEMENT TEAM

- Charles Stacey, MD - President & CEO
- Judy Walker, MD FRCPC - Chief Medical Officer
- Samuel Henderson, PhD - Chief Scientific Officer
- Jerris Knaisch - VP, Finance & North American Operations
- Cheryl Tan, BSc Pharm(Hons), MBA - VP, Commercial and Partnering
- Taryn Boivin, PhD - VP, CMC

PRODUCTS

Axona
Stage: Commercial
A medical food for the dietary management of Alzheimer's disease

Tricaprilin
Stage: Phase 2
An investigational drug for Alzheimer's disease

cerevance

ADDRESS:
One Marina Park Drive
14th Floor
Boston, MA 02210
United States

WEBSITE:
www.cerevance.com

EMAIL:
info@cerevance.com

PHONE:
+1 617 916 8936

COMPANY TYPE
Private

SECTOR:
Biotechnology
Neuroscience
Pharmaceuticals

YEAR FOUNDED:
2016

Cerevance, Inc.

COMPANY PROFILE

Cerevance is a pharmaceutical company focused on central nervous system diseases. Our strengths include a powerful technology platform, a pipeline of novel discovery-stage and clinical-stage compounds and a proven team. We believe that we are well positioned to deliver life-changing therapeutics for patients who have brain-related disorders.

MANAGEMENT TEAM

- Mark Carlton, Ph.D. - Chief Scientific Officer
- Nathaniel Heintz, Ph.D. - Chief Scientific Advisor
- Ted Hibben - Chief Business Officer
- David H. Margolin, M.D., Ph.D. - Senior Vice President, Clinical and Translational Medicine
- Brad Margus - Chief Executive Officer
- Robert Middlebrook - Chief Financial Officer

PIPELINE

Besides having a powerful discovery platform that may reveal new insights and therapeutic targets for brain diseases, Cerevance is now advancing preclinical and clinical programs for:

- Parkinson's disease
- L-Dopa induced dyskinesia
- Cognitive impairment
- Neuroinflammation
- Rett Syndrome

CLICK THERAPEUTICS™

ADDRESS
101 Avenue of the Americas
8th Floor
New York, NY 10013
United States

WEBSITE
www.clicktherapeutics.com

E-MAIL
info@clicktherapeutics.com

COMPANY TYPE
Private

SECTOR
Biotechnology
Digital Therapeutics
Medical Devices
Pharmaceuticals/Licensing

FOUNDED
2012

Click Therapeutics, Inc.

COMPANY PROFILE

Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click's Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes. Following a groundbreaking clinical trial, Click's industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click's lead prescription program is entering into a multi-center, randomized, controlled, parallel-group, phase III FDA registration trial for the treatment of Major Depressive Disorder in adults.

MANAGEMENT TEAM

- David Benshoof Klein – Co-Founder & CEO
- Randall Kaye, MD – Chief Medical Officer
- Christopher Jordan – Chief Technology Officer
- Ted Silver – Chief Financial Officer
- Joel Sangerman – Chief Commercial Officer
- Austin Speier – Chief Strategy Officer

FINANCIAL SUMMARY

In July 2018, Click announced a $17 million financing round led by Sanofi Ventures. Click is using this financing to continue advancing its proprietary platform and pipeline of prescription digital therapeutics to treat a wide range of diseases.

PIPELINE



ADDRESS:
2403 Sidney St.
Pittsburgh, PA 15203
United States

WEBSITE:
www.cogrx.com

EMAIL:
info@cogrx.com

PHONE:
+1 412 481 2210

COMPANY TYPE
Private

SECTOR:
Alzheimer's Disease
Biotechnology
Neurological Disorders
Pharmaceuticals
Small Molecule

YEAR FOUNDED:
2007

Cognition Therapeutics, Inc.

COMPANY PROFILE

Cognition Therapeutics is a privately held biopharmaceutical company focused on the creation and clinical development of a pipeline of disease-modifying small molecule drug candidates that restore and preserve the building blocks of brain health and function, the synapse. The company's lead candidate, Elayta™ (CT1812), was developed internally by a scientific team led by Susan Catalano, Ph.D., Cognition's founder and chief science officer. Elayta is a proprietary first-in-class, orally available small molecule in Phase 2 development for the treatment of mild-to-moderate Alzheimer's disease. In October 2017, the U.S. FDA granted Elayta Fast Track designation and the U.S. Patent Office issued a composition of matter patent for Elayta.

MANAGEMENT TEAM

- Kenneth I. Moch - President and CEO
- Susan Catalano, PhD - Chief Science Officer
- Hank Safferstein, PhD, JD - SVP, Corporate Development
- Stephen DiPalma - Chief Financial Officer
- Gilbert M. Rishton, PhD - Chemistry Advisor
- Michael Grundman, MD - Chief Medical Advisor
- Celine Houser - Vice President, Clinical Operations

PIPELINE

Elayta, a highly brain penetrant small molecule with a unique disease-modifying synaptorestorative mechanism of action, is currently in Phase 2 clinical testing for mild-to-moderate Alzheimer's disease. This orally dosed drug candidate, which was discovered by Cognition's scientific team led by Susan Catalano, Ph.D., facilitates the protection and restoration of synaptic function by selectively displacing toxic beta amyloid oligomers from their synaptic receptors, thus stopping downstream damage and improving memory function.

Results of a Phase 1b/2a clinical trial (COG0102) demonstrated that Elayta significantly reduced concentrations of synaptic damage proteins in the cerebrospinal fluid of patients with mild-to-moderate Alzheimer's disease. This reduction is consistent with the drug having a positive effect on synapses and with Elayta's synaptoprotective mechanism of action. Patient dosing has since commenced in three clinical studies of Elayta: SPARC (Synaptic Protection for Alzheimer's Restoration of Cognition), SNAP (AβO Displacement from Synapses on Neurons in Alzheimer's Patients) and SHINE (Synaptic Health and Improvement of Neurological Function with Elayta). Each of these studies are funded by grants from the National Institute on Aging of the National Institute of Health (award numbers RF1AG057780, RF1AG057553 and R01AG058660).

FINANCIAL SUMMARY

Cognition has funded operations and clinical development of Elayta through dilutive and non-dilutive capital totaling almost $80 million, including non-dilutive grant funding totaled over $40.0 million primarily from the National Institute of Aging.

ADDRESS:
10070 Barnes Canyon Rd.
Suite 100
San Diego, CA 92121
United States

WEBSITE:
www.cvsciences.com

EMAIL:
ir@cvsciences.com

PHONE:
+1 866 290 2157

COMPANY TYPE
Public

TICKER
[OTCMKTS:CVSI]

SECTOR:
Biotechnology
Neuroscience

YEAR FOUNDED:
2012

CV Sciences, Inc.

COMPANY PROFILE

MISSION
At CV Sciences, our mission to improve well-being underscores our values, operations, and products.

OVERVIEW
CV Sciences operates two distinct divisions: pharmaceuticals and consumer products. These divisions are supported by our medical and scientific advisors and state-of-the art production facilities.

PHARMACEUTICALS
CV Sciences' Pharmaceutical Division is developing synthetically-formulated cannabidiol-based medicine, pursuing the approval of the U.S. Food and Drug Administration (FDA) for drugs with specific indications utilizing cannabidiol as the active pharmaceutical ingredient.

CONSUMER PRODUCTS
CV Sciences' Consumer Products Division delivers botanical-based cannabidiol products that enhance quality of life. Currently distributed nationally in health food stores, health care providers' offices and online, our consumer products brand is backed by a formal safety review, growing body of case reports, and physicians' recommendations.

MANAGEMENT TEAM

- Joseph Dowling - Chief Executive Officer & Chief Financial Officer
- Michael J. Mona, III - President, Co-Founder & Chief Operating Officer
- Stuart Tomc - Senior Vice President, Business Development

PIPELINE

CV Sciences is in development of CBD-based potential FDA approved drugs. In December 2015, CV Sciences acquired CanX Inc., a pre-clinical drug development company focused on significant unmet medical needs. The initial drug candidate (CVSI-007) is a dosage form containing nicotine and synthetic CBD to support cessation of smokeless tobacco use and addiction.

INDICATION	PRODUCT	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3
Smokeless Tobacco Cessation	CVSI-007				

DEMIURGE TECHNOLOGIES
Humble souls, daring minds

ADDRESS:
Hofstrasse 1A
Zug, 6300
Switzerland

WEBSITE:
www.demiurge.technology

EMAIL:
crew@demiurge.ch

COMPANY TYPE
Emerging

SECTOR:
Biotechnology
Neuroscience
Robotics

YEAR FOUNDED
2015

Demiurge Technologies AG

COMPANY PROFILE

Demiurge is an AI-driven aetiology-first CNS drug discovery and development company in Switzerland with US$11MM raised since 2016. Demiurge's business model is to build new companies (NewCos) with wordwide top-tier VC/mgmt/sci co-founders for each disease-specific aetiology and associated first-in-class pipelines discovered at Demiurge. Demiurge is now building the first NewCo with AI-discovered aetiology of Alzheimer's Disease, there will be 2 more NewCos built with novel aetiologies of Parkinson's Disease and FTD/ALS in 2020.

MANAGEMENT TEAM

- Bragi Lovetrue - Founder CSO & CTO

INVESTMENT OPPORTUNITY

NewCo formation with top-tier VC/Mgmt/Sci co-founders to develop multi GFIC pipelines from AI-discovered causal aetiologies of AD,PD & FTD/ALS.

ENGAGE THERAPEUTICS

ADDRESS:
Summit, NJ
United States

WEBSITE:
www.engagetherapeutics.com

COMPANY TYPE
Private

SECTOR:
Biotechnology
Pharmaceuticals/Licensing

YEAR FOUNDED
2017

Engage Therapeutics, Inc.

COMPANY PROFILE

In 2016, Dr. Jacqueline French of NYU Langone Comprehensive Epilepsy Center told Greg Mayes about Staccato Alprazolam, an easy-to-use, hand-held inhaler in a phase 2a clinical trial with the potential to be the first rescue treatment of its kind that could terminate the current seizure. A seasoned pharmaceutical executive with decades of experience in the industry, Greg realized that he had the background and know-how it took to make Staccato Alprazolam a reality for the epilepsy community. Working with leading epileptologists, neurologists, and healthcare executives, Greg founded Engage Therapeutics with the goal of successfully completing the phase 2b clinical trial required for FDA approval and ultimately bringing the epilepsy community its first viable rescue treatment to terminate a seizure.

In 2017, Engage Therapeutics entered into an exclusive license and supply agreement with Alexza Pharmaceuticals to advance Staccato Alprazolam into phase 2b development as a treatment to stop seizure activity. The clinical trial began in 2018 in study sites across the United States as part of the process required to gain FDA approval and bring the product to market. The phase 2b clinical trial aims to assess the efficacy and safety of Staccato Alprazolam in treating naturally-occurring seizures. Engage has recently completed the 8 patient open label run in of the phase 2B with successful results and is starting the 100 patient randomized portion in early December with a goal of completing the trial in Q3 2019.

MANAGEMENT TEAM

- Gregory T. Mayes - President, Chief Executive Officer and Founder
- Jouko Isojarvi MD, PhD - Executive Vice President, Chief Medical Officer and Founder

KalGene Pharmaceuticals, Inc.

ADDRESS:
6100 Royalmount
Montreal, QC, H4P 2R2
Canada

WEBSITE:
www.kalgene.com

EMAIL:
info@kalgene.com

PHONE:
+1 604 375 4519

COMPANY TYPE
Private

SECTOR:
Biotechnology
Therapeutics

YEAR FOUNDED:
2016

COMPANY PROFILE

KalGene is developing a unique therapy intended to treat patients suffering from Alzheimer's disease (AD), which is a progressive and non-reversible neurodegenerative disorder. KalGene's product is designed to slow or halt progression of this devastating disorder, absent the side effect profile of the leading potential therapies in the pipeline.

KalGene has advanced into preclinical development a molecule designed to address both limitations cited above by in-licensing two technologies from the NRC. The first is utilization of a naturally occurring peptide which disrupts the oligomerization of the amyloid peptide, reducing it to a monomeric, non-toxic form. This approach avoids direct activation of the immune system which antibody-based therapies have encountered, resulting in frequent adverse events and significant reduction of the therapeutic window. The second advance is the incorporation into the molecule of a binding domain that targets a receptor on the blood-brain barrier, which facilitates rapid transport into the brain. Such approaches have been shown to increase by over 10-fold the amount of drug being delivered to the brain.

There are no other companies developing a disease-modifying biologic to treat Alzheimer's disease that is actively transported from blood to the brain. In addition, KalGene's product is designed to overcome the safely issues with the antibodies currently in development.

The company Is currently seeking investors in an extension of the Series A and will advance the product into early phase clinical studies to demonstrate target engagement and safety prior to seeking partnering opportunities.

MANAGEMENT TEAM

- Dr. James Callaway – Chief Executive Officer
- Dr. T. Nathan Yoganathan - President and Chief Scientific Officer
- Dr. John W. Gillard – Senior Vice President Product Development

PIPELINE



M3 BIOTECHNOLOGY

ADDRESS:
4000 Mason Rd, Suite 300
Box 352141
Seattle, WA 98195
United States

WEBSITE:
www.m3bio.com

EMAIL:
info@m3bio.com

PHONE:
+1 206 221 8112

COMPANY TYPE
Private

SECTOR:
Biopharma
Neuroscience

YEAR FOUNDED:
2011

M3 Biotechnology, Inc.

COMPANY PROFILE

M3 Biotechnology (M3) is a clinical-stage therapeutics company with a platform of regenerative small molecule therapeutics with the potential to permanently alter the course of disease.

M3's novel assets employ a completely different mechanism of action than current investigational and approved approaches by acting on a neurotrophic factor of a highly conserved mechanism of action. In addition to Alzheimer's, the core technology and lead candidate has the potential to impact neurodegenerative therapies broadly, including Parkinson's. Unlike drugs on the market for Alzheimer's and Parkinson's which offer only symptomatic relief, M3's lead candidate offers the potential to slow or halt degeneration and potentially restore lost function.

Phase 1a and Phase 1b clinical trials with its lead compound, NDX-1017, have been completed in healthy young and elderly individuals assessing safety, toxicity and tolerability while also evaluating a biomarker strategy. Phase 1b clinical trials in Alzheimer's patients are ongoing.

MANAGEMENT TEAM

- Leen Kawas, PharmD, PhD - President & CEO
- Glenna Mileson - CFO

PIPELINE



ADDRESS:
Gerbergasse 30
CH-4001, Basel
Switzerland

WEBSITE:
www.metys-pharma.ch

EMAIL:
info@metys-pharma.ch

PHONE:
+41 79 408 79 82

COMPANY TYPE
Private

SECTOR:
Biotechnology
Neuroscience

YEAR FOUNDED:
2013

Metys Pharmaceuticals AG

COMPANY PROFILE

Metys Pharmaceuticals is a drug discovery and development company located in Basel, Switzerland. Founded in 2013, the company is developing proprietary modulators of glutamate signalling for the treatment of central nervous system disorders and diseases. The lead candidate, MP-101, is a Phase 2-ready orally-active small molecule being prepared for Phase 2 clinical trials for prevention of chemotherapy-induced peripheral neuropathy and treatment of diabetic peripheral neuropathy.

MANAGEMENT TEAM

- Michael Scherz - Founder & CEO
- Elisabet Lindberg - CMO
- Carlo Farina - Head of Chemistry & Patents

PIPELINE



ADDRESS:
130 North Marina Dr
Long Beach, CA 90803
United States

WEBSITE:
www.nemusbioscience.com

EMAIL:
hello@nemusbio.com

PHONE:
+1 949 396 0330

COMPANY TYPE
Public

TICKER
[OTC: NMUS]

SECTOR:
Biotechnology
Medical Cannabis
Neuroscience

YEAR FOUNDED:
2011

NEMUS Bioscience, Inc.

COMPANY PROFILE

Nemus Bioscience (OTC: NMUS) is a publicly traded biotech company located in Southern California, dedicated to the development of bioengineered cannabinoid molecules designed to address multiple diseases, especially those of high unmet need. The molecules are derivatives of molecules typically found in the Cannabis plant and include a prodrug of THC and an analog of CBD. These synthetically produced compounds are designed to enhance bioavailability and pharmacokinetics resulting in therapies that can be optimized to treat specific disease states and are proprietary by virtue of a global patent footprint that includes composition of matter, methods of use, methods of synthesis and methods of formulation. Current markets addressed are global, multi-billion dollar opportunities led by ocular diseases such as glaucoma. Nemus is the only cannabinoid company with a multi-cannabinoid platform to address diseases of the eye.

MANAGEMENT TEAM

- Brian Murphy , MD, MPH, MBA - Member – Board of Directors, Chief Executive Officer and Chief Medical Officer
- Doug Cesario - Chief Financial Officer
- Wendy Cunning - Vice President Business Operations

PIEPELINE



ADDRESS:
913 North Market Street
Suite 200
Wilmington, DE 19801

WEBSITE:
www.neurorxpharma.com

EMAIL:
investors@neurorxpharma.com

COMPANY TYPE
Private

SECTOR:
Biotechnology
CNS
Neuroscience
Small Molecule

YEAR FOUNDED:
2015

NeuroRx, Inc.

COMPANY PROFILE

NeuroRx draws upon 30 years of basic science and clinical expertise in the role of N-methyl-D-aspartate (NMDA), a receptor that regulates human thought processes, particularly depression and suicidality, as well as PTSD. The Company's lead product, NRX-101, has received FDA Breakthrough Therapy Designation, a Special Protocol Agreement, and a Biomarker Letter of Support for the treatment of Severe Bipolar Depression with Acute Suicidal Ideation or Behavior. NRX-101 and its related pipeline is protected by six families of patents with 45 pending applications and more than 30 allowances worldwide. Phase 2 data demonstrated a significant reduction in depression (11 points on MADRS-10, p=0.03) between NRX-101 and standard therapy (lurasidone) at 14 days. The company is privately funded and led by former senior executives of Johnson & Johnson, BMS, Pfizer Inc., Eli Lilly, and Sunovion. NeuroRx's Board of Directors and Advisors includes Hon. Sherry Glied, former Assistant Secretary for Planning and Evaluation, Department of the U.S. Health and Human Services; Chaim Hurvitz, former President, TEVA International Group; Wayne Pines, former Associate Commissioner of the U.S. Food and Drug Administration, and Daniel Troy, former Chief Counsel, U.S. Food and Drug Administration.

MANAGEMENT TEAM

- Jonathan C. Javitt, MD, MPH – Chief Executive Officer
- Fred Grossman, DO – Chief Medical Officer
- Richard Siegel, PhD –EVP Drug Development
- Robert Besthof, MIM – Chief Commercial Officer

PIPELINE

NRX-101 is a patented, oral, fixed-dose combination of two FDA approved drugs: D-cycloserine, a N-methyl-D-aspartate (NMDA) receptor modulator, and lurasidone, which has D2/5-HT2a receptor antagonist activity. D-cycloserine has shown activity against depression in four clinical studies. It has also shown an effect on suicidality in some of these studies. NRX-101 is designed to address bipolar depression with suicidal ideation, an indication for which there is no currently approved drug and for which the only FDA-approved treatment remains electroconvulsive therapy (ECT). NeuroRx was granted Fast Track designation by the U.S. FDA for this indication in August 2017. In May of 2018 NeuroRx was awarded a Special Protocol Agreement (SPA) by the FDA for the NRX-101 phase 2b/3 trial. In April 2018, NeuroRx received a biomarker letter of support from the FDA, documenting that the company had shared evidence of increased Glx levels associated with oral administration of D-cycloserine, a phenomenon not seen with serotonin-targeted (SSRI). In November 2018, the FDA awarded NeuroRx Breakthrough Therapy designation for NRX-101.

ORYZON

ADDRESS:
SPAIN ORYZON (Labs)
C/Sant Ferran 74
08940 Cornellà de Llobregat
Barcelona, Spain

USA ORYZON
245 First Street
Suite 1800
Cambridge, MA 02142

WEBSITE:
www.oryzon.com

EMAIL:
info@oryzon.com

PHONE:
+34 93 515 1313
+1 617 444 8786

COMPANY TYPE
Public

TICKER
[BME: ORY]

SECTOR:
Epigenetics
Neuroscience
Oncology & Inflamation

YEAR FOUNDED:
2000

Oryzon Genomics S.A.

COMPANY PROFILE

Oryzon is a public clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics.

From its founding in 2000 through 2008, the company focused its efforts in growing a functional genomics platform business model, In 2008, with the acquisition of Crystax Phar-maceuticals, we started our drug discovery programs in oncology and neurodegenerative diseases. Our business model is to develop our proprietary drug candidates till mid clinical stage, at which point it is decided on a case-by-case basis to either keep the development in-house or to partner or outlicense the compound for late stage development and commercialization.

Oryzon is listed on the Spanish Stock Exchange since December 2015 (ORY, ISIN Code: ES0167733015). In the period 2015-2016, the company raised €32M, with additional Pipes in 2017 (€18.2M) and 2018 (€13M) where the company incorporated specialized investors from US and Europe.

The company has a broad and growing portfolio, with two compounds in clinical trials, Iadademstat (ORY-1001), a highly potent and selective LSD1 inhibitor that has been granted orphan-drug status by EMA, in Phase IIA in oncology, and Vafidemstat (ORY-2001), a LSD1/MAO-B inhibitor , also in Phase IIa, dual for the treatment of mild to moderate Alzheimer's disease, multiple sclerosis. Vafidemstat is al being explored in a basket trial to treat aggressiveness in psychiatric conditions like ASD, ADHD and BLP and other neurodegenerative diseases. The company has another compound ready to start Phase I, ORY-3001, a selective LSD1 inhibitor for the treatment of non-oncological diseases, and additional earlier programs in other cancer indications.

From 2014 to 2017 the company had a collaboration with Roche relating to our lead oncology program and received +$23M. This asset is now being developed by Oryzon. The company has also obtained competitive US and European grants in the amount of €8M to support the development of Vafidemstat (ORY-2001) since the start of our CNS research.

The company has a seasoned executive management with vast experience in the industry.

MANAGEMENT TEAM

- Carlos Buesa - Chief Executive Officer
- Tamara Maes - Chief Scientific Officer
- Roger Bullock - Chief Medical Officer
- Michael T Ropacki – Chief of Clinical and Product Development
- Sonia Gutierrez - Chief of Clinical Operations
- Enric Rello - Chief Operating Office, Chief Financial Officer in Spain
- Emili Torrell - Chief Business Development Officer
- Neus Virgili - Chief Intellectual Property Officer

Oryzon PIPELINE



(1) Approved. Recruitment ongoing
(2) Approved
(3) CTA submitted

paxNeuroscience

ADDRESS:
1113 Juniper Terrace
Glenview, IL 60025
United States

WEBSITE:
www.paxneuroscience.com

PHONE:
+1 847 998 6883

COMPANY TYPE
Emerging

SECTOR:
Neurodiagnostics
Therapeutics

YEAR FOUNDED:
2009

Pax Neuroscience, Inc.

COMPANY PROFILE

Pax Neuroscience focuses on the neurobiology of depression and antidepressant action to deliver a family of products designed to facilitate depression diagnosis, tailor depression therapeutics, aid Pharma in designing new antidepressants and develop conceptually novel drugs for depression. Pax is committed to transforming the standard of care for depression.

Depression is the leading cause of disability, worldwide, affecting one in six of us at some point in our lifetime. In the US alone, total annual costs of depression are estimated at more than $200B. Depression diagnosis, often done by primary care physicians, who treat about 80% of depression, is subjective and often inaccurate. One third of those with depression do not seek treatment and most antidepressants require 2 months to achieve clinical efficacy, making trial and error drug selection the norm. One third of those with depression do not respond to any drug, increasing their risk for suicide.

Pax Neuroscience has developed a protein-based depression biomarker from blood cells that can be used to confirm depression diagnosis and then to guide and personalize drug therapy. In addition, Pax has developed a cell-based screen that is being used by Pharma to select compounds with antidepressant potential. Prior and current studies have been conducted via two NIH SBIR/STTR grants. Data from SBIR sponsored Phase 1 clinical trial is currently being analyzed. Pax technology is protected by 3 patents.

MANAGEMENT TEAM

- Mark M. Rasenick, PhD. - Co-Founder, President, Chief Scientific Officer
- Helene J. Shambelan, J.D. - CEO

PIPELINE

MOODMARK

MOODMARK Dx is a quantitative blood test that will change the standard of care to facilitate diagnosis and care for depression. Pharma can also use this to select subjects for clinical trials.

MOODMARK Rx uses the blood test to provide an indication of treatment response within 1 week after start of treatment. Current treatment allows for slow (6-12 weeks) for clinical response to antidepressant.

MOODMARK Personalized is a platform that screens a patient's own cells against a panel of antidepressant drugs. Current existing technologies cannot predict clinical response prior to treatment..

MOODMARK Screen will identify potential antidepressants. Unlike current screening tools, it considers time lag in antidepressant response.

Pharmaleads
ENKEPHALIN-POWERED PAIN RELIEF

ADDRESS:
11, rue Watt
75013, Paris
France

WEBSITE:
www.pharmaleads.com

EMAIL:
info@pharmaleads.com

PHONE:
+33 1 44 06 70 00

COMPANY TYPE
Private

SECTOR:
Biotechnology
Neuroscience
Pharmaceuticals

YEAR FOUNDED:
2000

Pharmaleads SA

COMPANY PROFILE

Pharmaleads aims to provide patients suffering from severe chronic and acute pain with improved pain relief without the side effects associated with other classes of analgesics.

Based on years of experience in the design of highly potent and specific inhibitors of enkephalinases, Pharmaleads has developed a new class of analgesics called DENKIs (Dual Enkephalinases inhibitors). These small molecules are able to provide patients with local and sustainable pain relief.

Pharmaleads' DENKIs are first-in-class drugs with a novel mechanism of action tackling pain by using endogenous enkephalins, natural peptides that specifically bind to pain-related opioid receptors to naturally modulate pain without the side effects observed with exogenous opioid drugs that also bind to other opioid receptors, not involved in pain control and thus triggering multiple side effects.

Pharmaleads believes its products can change the lives of the many patients in need of improved treatment options for their chronic and/or acute pain, and could offer healthcare providers with a safe pain management option that helps address the opioid epidemic.

MANAGEMENT TEAM

- Thierry Bourbié, Co-Founder, Chief Executive Officer & Chairman
- Pierre Maillard, Chief Financial Officer
- Michel Wurm, VP, Medical Affairs, Strategy & Business Development
- Tanja Ouimet, Director of Clinical Development
- Hervé Poras, Director of CMC and Preclinical Operations

PIEPELINE

ADDRESS:
1920 Yonge Street
Suite 200
Toronto, ON M4S 3E2
Canada

WEBSITE:
www.promisneurosciences.com

EMAIL:
eugene.williams@
promisneurosciences.com

PHONE:
+1 617 460 0978

COMPANY TYPE
Public

TICKER
[TSE:PMN]
[OTCQB:ARFXF]

SECTOR:
Biotechnology
Neuroscience

YEAR FOUNDED:
2004

ProMIS™ Neurosciences, Inc.

COMPANY PROFILE

ProMIS™ Neurosciences, Inc., headquartered in Toronto Ontario with offices in Cambridge Massachusetts, is publicly traded on the Toronto Stock Exchange (ticker symbol: PMN.TO) and OTCQB (ticker symbol: ARFXF). ProMIS is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD).

MANAGEMENT TEAM

- Eugene Williams - Executive Chairman
- Dr. Elliot Goldstein - President and CEO
- Dr. Neil Cashman - Chief Scientific Officer and Co-founder
- James W. Kupiec, MD - Chief Medical Officer
- Steven Plotkin, PhD - Chief Physics Officer
- Johanne Kaplan, PhD - Chief Development Officer
- Daniel Geffken - Chief Financial Officer
- Ernest D. Bush, PhD - Head of Pharmacology/Toxicology
- Russell Blacher - Head of Manufacturing

PIEPELINE



*Multiple dose phase 1 to include biomarkers for early evaluation of potential signs of neuronal protection

Regenera

ADDRESS:
18 Einstein St., Science Park
Ness-Ziona
Israel

WEBSITE:
www.regenerapharma.com

EMAIL:
admin@regenerapharma.com

PHONE:
+972 8 9316304

COMPANY TYPE
Private

SECTOR:
Biotechnology
Neuroscience

YEAR FOUNDED:
2008

Regenera Pharma Ltd.

COMPANY PROFILE

Regenera Pharma, a clinical stage company, develops RPh201, a drug product for the treatment of neurological disorders. RPh201 is a well-defined botanical extract that has been observed to regenerate neural cells and restore function in preclinical and clinical studies. Regenera is currently running a Phase 3 trial in NAION (Nonarteritic Anterior Ischemic Optic Neuropathy) in the U.S. and a Phase 2 trial in Alzheimer Disease in Canada. Results are expected by the end of 2019. Regenera has a strong IP portfolio, consisting of 9 family patents that cover the drug's use and its composition . CMC development plan is supported by the FDA. Regenera's dedicated team, made up of highly experienced industry veterans, is working tirelessly and meticulously to achieve the Company's goal.

MANAGEMENT TEAM

- Jordan Rubinson, MS, MBA – CEO
- Zadik Hazan, MD, MS Immunology – CSO, Founder
- Sharon Falach-Kovalsky – CFO
- Konstantin Adamsky, PhD – VP Operations
- Orna Palgi, PhD – VP R&D
- Yoni Weiss, MD, MBA – CMO
- André Lucassen, PhD – Senior Director CMC & IP

CLINICAL DEVELOPMENT

NAION

Regenera is in the midst of a multi-center Phase 3 study in 12 leading centers in the U.S. The study is a double-masked study to evaluate the efficacy and safety of RPh201 treatment in subjects with previous NAION. A Fast Track designation was recently granted from the FDA.

ALZHEIMER'S DISEASE

Regenera is running a multi-center Phase 2 study in 5 centers in Canada. This six-month, double-blind Phase 2 study will evaluate the safety, tolerability and clinical benefit of RPh201 in individuals with Alzheimer's Disease, with or without coexisting cerebrovascular disease.

PIPELINE

ADDRESS:
750 Third Avenue
9th Floor
New York, NY 10017
United States

WEBSITE:
www.relmada.com

EMAIL:
info@relmada.com

PHONE:
+1 212 547 9591

COMPANY TYPE
Public

TICKER
[OTCMKTS: RLMD]

SECTOR:
Biotechnology
Neuroscience

YEAR FOUNDED:
2004

Relmada Therapeutics, Inc.

COMPANY PROFILE

Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines for areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada lead program, dextromethadone (REL-1017), is an orally administered N-methyl-D-aspartate receptor (NMDAR) antagonist, which is currently tested as a treatment for depression in a Phase 2 study. REL-1017 is active on the NMDAR ketamine binding site and has demonstrated an overall favorable safety profile without ketamine psychotomimetic adverse reactions in two Phase 1 studies. In preclinical studies, REL-1017 showed antidepressant efficacy and effects on neuronal activity similar to that of ketamine. The U.S. Food and Drug Administration granted Fast Track designation for dextromethadone for the adjunctive treatment of MDD.

MANAGEMENT TEAM

- Sergio Traversa, PharmD, MBA - Chief Executive Officer and Interim Chief Financial Officer
- Dr. Ottavio Vitolo, MD - Senior Vice President, Head of R&D and Chief Medical Officer

PIEPELINE

ADDRESS
601 Genome Way
Suite 2001
Huntsville, Alabama 35806
United States

WEBSITE
www.serinatherapeutics.com

E-MAIL
info@serinatherapeutics.com

PHONE
+1 256 327 0566

COMPANY TYPE
Private

SECTOR
Epilepsy
Movement Disorders
Onccology
Pain
Parkinson's Disease
Polymer Therapeutics

FOUNDED
2007

Serina Therapeutics, Inc.

COMPANY PROFILE

Serina Thearpeutics has developed a proprietary, clinical-stage polymer therapeutics technology based upon poly(2-oxazoline) – POZ. We have a pipeline of small molecule polymer conjugates that are being developed for Parkinson's disease (PD), pain, epilepsy and oncology. At this meeting you will hear about SER-214, a polymer conjugate of rotigotine that has completed Phase Ia in PD. SER-214 provides continuous drug delivery following a single weekly SC injection. In addition, we will present preliminary data on the development of SER-240/241, a polymer conjugate of apomorphine that provides continuous drug delivery of apomorphine following a single SC injection. Unlike current formulations of apomorphine, which result in inflammatory skin reactions and nodule formation – SER-240/241 does not promote any skin reactions when administered as a SC injection. SER-214 is being developed for early PD, and SER-240/241 is being developed for advanced PD.

Serina Therapeutics was founded by the chemists and management team that ushered in the first generation polymer technology known as PEG. That technology platform led to thirteen approved products that have generated in excess of $ 170 billion in revenue. POZ has properties that distinguish it from PEG and many other polymers that are being developed for therapeutics – these include clearance entirely by renal filtration, absence of accumulation by tissues in the body, and POZ is completely nonimmunogenic. We believe POZ represents the next generation in polymer therapeutics technology.

MANAGEMENT TEAM

- Randall W. Moreadith, MD, PhD – President and Chief Executive Officer
- Milton Harris, PhD – Founder and Chairman of the Board
- Mike Bentley, PhD – Founder and Chief Scientific Officer
- Tacey Viegas, PhD – Chief Operating Officer
- Brendan Rae, PhD, JD – Chief Business Officer

PIPELINE

Serina Therapeutics is developing proprietary drugs to treat neurological diseases, cancer and pain. In addition, we are partnering the POZ™ platform to develop pharmaceuticals for other companies – which include antibody drug conjugates, proteins and small molecules. The POZ drug conjugate platform is broad, customizable and versatile, and can be dosed via IV, SC or IM routes.

*SER-214 is a first-in-class drug for two major dopamine-responsive disorders. Click the blue circles above to learn more about SER-214.

STALICLA

ADDRESS
Campus Biotech Innovation Park
Avenue de Sécheron 15
1202, Genève
Switzerland

WEBSITE
www.stalicla.com

E-MAIL
info@stalicla.com

PHONE
+41 22 545 12 42

COMPANY TYPE
Emerging

SECTOR
Autism Spectrum Disorder
Biotechnology

FOUNDED
2017

Stalicla SA

COMPANY PROFILE

STALICLA is an autism spectrum disorder (ASD) focused, data guided, drug development biotech company incorporated in May 2017. Through an innovative systems biology-based platform (DEPI) STALICLA has been able to identify non-behavioral subgroups of patients with idiopathic ASD and corresponding first-in class treatment candidates, thus pioneering personalized medicines for ASD.

KEYPOINTS

- Q1 2018 successful closure of $4M seed round
- Development of a strong ecosystem with Key Opinion Leaders in the field of ASD (including Paul Wang as advisor to the SAB)
- February 2018, STALICLA listed among the top 50 startups in Switzerland (Business magazine BILAN classification)
- March 2018, first clinical validation of the ASD Ph1 subgroup through observational clinical trial at the Greenwood Genetic Center (SC, USA)
- April 2018, listing of STALICLA among emerging biotech to follow by Canaccord Genuity, a global financial services firm with strong focus on healthcare sector
- May 2018, official launch of STALICLA's clinical development program with worldwide leading CRO, PPD.
- July-August 2018, results supporting specific biological profile in ASD phenotype 1 vs other patients with ASD vs controls. Potential for first in class biomarker in idiopathic Autism Spectrum disorder
- September 2018, positive EPO Search Report with "intention to grant" for STP1 COM patent. Operating parallel EU - US and international filling strategy.
- October-November 2018, Incorporation of STALICLA's Computational Systems Biology physical HPC unit in Barcelona, Spain – incl. 4 FTE computational biology data scientists.
- November 2018, international patent applications, request for examination of the STP1 COM patent in USA, EU and other countries, filling new EU patent application and US provisional patent on specific metabolomic profile of ASD Ph1
- November 2018, first results supporting efficacy of STP1 on metabolomic profile of ASD Ph1 patients.

MANAGEMENT TEAM

- Lynn Durham – MSc – CEO & Founder
- Luigi Boccuto- MD – Chief Scientific Officer
- Jean-Marc Hyvelin – Head of Research Partnerships and Innovations
- Joseph Wettstein – PhD – Acting Chief of Development and Strategy
- Walter Kaufmann – MD – Chief Medical Officer
- Julien Cachat – Assistant Project Manager

PIPELINE

Databased Endophenotyping Patient Identification - DEPI



Early clinical development: ASD Phenotype 1 validated through observational clinical trial

First-in-class endophenotyping in Autism Spectrum Disorder (ASD)



Non-clinical development: metabolomic profile of ASD Phenotype 1 lymphoblastoid cell lines.

STP1: first in class treatment for ASD Phenotype 1

Non-clinical development: efficacy STP1 in ASD patient cell lines and *in vivo* model ongoing.

T3D Therapeutics, Inc.

ADDRESS:
68 T.W. Alexander Drive
PO Box 13628
Research Triangle Park, NC 27709
United States

WEBSITE:
www.t3dtherapeutics.com

EMAIL:
info@t3dtherapeutics.com

PHONE:
+1 919 237 4897

COMPANY TYPE
Private

SECTOR:
Alzheimer's Disease
Biotechnology
Huntington's Disease
Small Molecules
Therapeutics

YEAR FOUNDED:
2013

COMPANY PROFILE

T3D Therapeutics, Inc. was founded in 2013 to challenge the prevailing thinking over the last two decades in the development of solutions to effectively treat Alzheimer's disease. Our mission is to develop a ground-breaking, disease-modifying, new drug for the treatment of Alzheimer's disease (AD). Additionally, T3D Therapeutics is targeting treatments for other neurodegenerative diseases with an emphasis on Huntington's Disease (HD).

Fundamental to our approach to AD is the recognition that Alzheimer's disease is a neuro-metabolic disease characterized by insulin resistance. As such, we must first address poor glucose energy metabolism and dysfunctional lipid metabolism in the brain which leads to neurodegeneration as evidenced by plaques, tangles and inflammation.

The brain is the most metabolically active organ in the body and it relies on glucose for 'fuel'. If the brain loses its ability to efficiently process glucose into energy and maintain lipid homeostasis, the brain becomes 'starved'. This 'starvation' causes a wasting process that then leads to cognitive and motor function deficits – this is Alzheimer's disease.

Our lead product candidate, T3D-959, is positioned to become a transformational therapy by targeting both the brain 'starvation' (as a result of glucose and lipid metabolism dysfunction) and neurodegeneration of Alzheimer's disease and by treating multiple manifestations of the disease.

MANAGEMENT TEAM

- John Didsbury, Ph.D. - President & CEO, Chairman of the Board
- Warren Strittmatter, M.D. - Chief Medical Officer
- Stan Chamberlain, Ph.D. - Chief Scientific Officer
- Hoda Gabriel, PMP - Executive Director Clinical Development

PIEPELINE

Lead compound T3D-959 is in active development as a potentially disease-modifying, orally-delivered, once-a-day medicine for Alzheimer's disease patients with mild to moderate disease severity. A key tenet of the metabolic approach to treating Alzheimer's disease (AD) with T3D-959 is that AD involves a massive positive feedback loop of aberrant glucose and lipid metabolism intertwined with neurodegenerative 'triggers', e.g. plaques, tangles, inflammation, oxidative stress. T3D-959 is a PPAR delta/gamma dual nuclear receptor agonist designed to break this feedback loop by improving glucose energy and lipid metabolism dysfunctions in AD. The mechanism of action of T3D-959 provides a potential to improve dysfunctional glucose and lipid metabolism that is inherent in other neurodegenerative diseases, including certain orphan diseases, notably Huntington's disease (HD).



Tonix Pharmaceuticals Holding Corp.

ADDRESS:
509 Madison Avenue
Suite 306
New York, NY 10022
United States

WEBSITE:
www.tonixpharma.com

EMAIL:
investor.relations@tonixpharma.com

PHONE:
+1 212 980 9155

COMPANY TYPE
Public

TICKER
[NASDAQ:TNXP]

SECTOR:
Biotechnology
Neuroscience

YEAR FOUNDED:
2007

COMPANY PROFILE

Tonix is a research and development company that is focused on identifying promising new product candidates and advancing them through clinical development toward regulatory approval.

Tonix is currently focused on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense through potential medical counter-measures.

MANAGEMENT TEAM

- Seth Lederman, MD - Co-Founder, CEO & Chairman
- Gregory Sullivan, MD - Chief Medical Officer
- Bradley Saenger, CPA - Chief Financial Officer
- Jessica Edgar Morris - Chief Operating Officer
- Mark T. Edgar, PhD - Senior Vice President of Product Development

PIEPELINE



Vitality Biopharma, Inc.

ADDRESS:
1901 Avenue of the Stars, 2nd Floor
Los Angeles, CA 90067
United States

WEBSITE:
www.vitality.bio

EMAIL:
info@vitality.bio

PHONE:
+1 530 231 7800

COMPANY TYPE
Public

TICKER
[VBIO:US]

SECTOR:
Biotechnology
Cannabies
Neuroscience

YEAR FOUNDED:
2007

COMPANY OVERVIEW

Vitality Biopharma is unlocking the power of cannabinoid pharmaceuticals for treatment of serious neurological and inflammatory conditions. The Company's operations include federally-compliant cannabinoid drug development and the launch of a specialty care treatment network in the United States focused on the reduction of opioid dependence.

INVESTMENT HIGHLIGHTS

Vitality has developed a proprietary new class of cannabinoid prodrugs named cannabosides, including VBX-100, a THC prodrug, which avoids psychoactivity through targeted GI delivery.

Independent clinical results suggest that cannabinoids will help induce remission in Crohn's disease, and that the vast majority of inflammatory bowel disease (IBD)patients experience symptomatic relief, including 84% of patients who report improvement in visceral or pain.

Visiongain predicts that in 2018 drug revenues for treatment of IBD will reach $9.6 billion. The ultimate goal of clinical treatment is to obtain complete disease control and to stop disease progression. This includes remission of disease without use of steroids or opiates, normalization of inflammatory markers, and healing of the
mucosal lining of the gastrointestinal tract, leading to better clinical outcomes, reduced healthcare costs, and an improved quality of life.

MANAGEMENT TEAM

- Robert Brooke - CEO, Co-founder
- Richard McKilligan, JD, MBA - Controller
- Brandon Zipp, PhD - Director of R&D, Scientific Co-founder
- Dr. Reef Karim - Chief Medical Officer, Vitality Healthtech

PIPELINE

Drug	Clinical Indications	Status
VBX-100	Inflammatory Bowel Disease (including remission) Irritable Bowel Syndrome Narcotic Bowel Syndrome	Phase 1 trial to completed in 1st half of 2019; Phase 2 trials to be initiated in 2nd half of 2019
VBX-210	Inflammatory Bowel Disease (maintaining remission) Irritable Bowel Syndrome Opiate-Induced Bowel Dysfunction C. Difficile Infections Colorectal Cancer	Preclinical
Additional Cannabinoid Formulations	Complex/Refractory or Neuropathic Pain (substitution therapy for opioid painkillers) Autism Multiple Sclerosis & Rare White Matter Disorders Guillain-Barre	Observational clinical studies to initiate in 1st half of 2019

SILVER SPONSOR

Emerald Health Pharmaceuticals, Inc.

emeraldpharma.life

Emerald Health Pharmaceuticals is focused on treating life-threatening diseases through cannabinoid science. By combining decades of life science and drug development experience with industry-leading expertise in cannabinoid science, EHP is discovering, developing and commercializing proprietary cannabinoid-derived medicines that address significant unmet needs. Currently, EHP is advancing two families of new chemical entities (NCE), derived from cannabidiol (CBD) and cannabigerol (CBG) that it has modified through rational drug design to affect validated receptors pertinent to targeted diseases. Its lead drug candidate, EHP-101, a synthetic derivative of CBD, is focused on treating multiple sclerosis and scleroderma. Its second, EHP-102, a synthetic derivative of CBG, is focused on treating Huntington's disease and Parkinson's disease. The company intends to launch a Phase I clinical study of EHP-101 in 2018.

SUPPORTERS

BioPartner

www.biopartner.co.uk

BioPartner is an independent, government-accredited trade organisation, promoting international partnering for trade, investment and collaborations with UK Life Science companies. BioPartner's delegations promote the UK presence at major internation-al biopharma conferences, and companies are assisted with access to government grants and heavily discounted entry fees. Through the BioPartner Programme, mem-bers receive extra benefits and support to effectively trade overseas.

Biotechgate

www.biotechgate.com

Biotechgate is a global, comprehensive, life science database covering the Biotech, Pharma and Medtech industries. There are currently over 36,000 company profiles on the Biotechgate database. Biotechgate is commonly used to find product pipelines, collaboration partners, in/out-licensing opportunities and information about technology platforms, management details, new business leads and financing rounds. In addition, our licensing deals database supports companies in negotiating their licensing agreements.

Citigate Dewe Rogerson

www.citigatedr.co.uk

Citigate Dewe Rogerson is one of the world's leading strategic communications consultancies.
Our Life Sciences team has established a reputation for excellence spanning financial, corporate and scientific communications; this has enabled us to become trusted advisors and to build a broad portfolio including some of the most innovative and exciting international life sciences companies. Our clients are at all stages of development, from start-up to multinationals, and our activities are focused on delivering campaigns that support corporate objectives. As a result, we have been involved in major corporate transactions and events in the life sciences sector over the past decade such as IPOs, other public and private fundraisings, and M&As.

Recent IPO transactions: ABIVAX (Euronext Paris - €60m), OSE Pharma (Euronext Paris - €21m), Nordic Nanovector (Oslo – NOK575m), Midatech Pharma (London AIM - £32m), Abzena (London AIM - £20m), arGEN-X (Brussels - €42m), Pixium Vision (Euronext Paris - €39.5m), Crossject (Euronext Paris - €17m). Other recent financings: Abingworth (£225m ABV VI), Rigontec (€14.25m Series A), Calcivis (£4.5m fundraising), ViraTherapeutics ($3.6m - Series A). Recent M&A: Heptares (up to $400m acquisition by Sosei), Prosonix (up to £100m acquisition by Circassia), bioquell (Sale of subsidiary for £44.5m).

Edison Group

www.edisongroup.com

Edison is an international advisory firm with around 450 corporate clients and 110 people working from offices in London, New York, Frankfurt, Sydney and Wellington. The team consists of 80 analysts, investment and logistics professionals with experience in capital markets, investor roadshows and communications. Healthcare is Edison's largest sector, with 16 analysts covering over 100 biotech and medtech stocks across the UK, continental Europe, North America and Asia-Pacific.

FreeMind

www.freemindconsultants.com

FreeMind is a consulting group whose goal is to assist in maximizing potential to receive funding from non-dilutive sources. Established in 1999, FreeMind is the largest consulting group of its kind working with academics and Industry alike. FreeMind's proven long-term strategic approach has garnered its clients over 1.5 billion dollars to date.

Our expertise in applying for grants and contracts extends throughout every government mechanism open to funding the life sciences including all NIH institutes, DoD, NSF, FDA, CDC, BARDA, etc., as well as private foundations.

FreeMind's knowledgeable and experienced team of Client Strategists and Project Managers are dedicated to guiding non-dilutive funding efforts from identification of the most suitable opportunity through to submission and subsequent award. Our team of experts will assist in making non-dilutive funding a key tool in a long-term financial strategy.

Instinctif Partners

www.lifesciences.instinctif.com

Instinctif Partners is an international business communications consultancy. With a track record of delivering truly creative programmes, the Life Sciences practice focuses on enhancing the value proposition for companies seeking investment, partnerships or customers. Our core skill is working with clients to communicate the value of their science and innovation to key stakeholders through the most relevant channels: crafting communications solutions that showcase each company, product or technology. Specifically, we are unique in offering specialist expertise seamlessly across corporate, financial, healthcare and marketing communications with outreach programmes to media, industry, professional, public, financial and investment communities. Our service offering covers all communications disciplines including strategic counsel, PR, IR, media relations, public affairs, crisis communications, internal communications, marketing, advertising, copywriting, design, research and event management. Our globally integrated and dedicated life sciences team serves clients around the world from our headquarters in London, and bases across Europe, AsiaPac and the USA.

MedTech Strategist

www.medtechstrategist.com

MedTech Strategist, a leading information and investment conferences provider focused exclusively on the rapidly evolving global medical device industry, is led by managing partners and co-editors-in-chief David Cassak and Stephen Levin, along with a seasoned editorial team and staff. With more than 100 years of combined experience, our team provides our community with both breadth and depth in our industry publication, MedTech Strategist, and access to unparalleled connections at our global investment and partnering conferences. In addition, the MedTech Strategist Community Blog complements the strategic medtech industry coverage that our publication is known for, with candid video interviews and short perspective articles focusing on the people and the passionate innovation behind the most exciting trends in the global device space. Think Strategically. Join Our Community.

Platform Life Sciences

www.goingpublic.de/lifesciences

The Life Sciences-Series - Launched in 2014 four issues of the Life Sciences-Series appear annually. Based on the three pillars – technology, financing, investment – the issues combine current topics of life sciences with knowledge and networking from corporate financing and capital market. The mission: Building a cross medial bridge between the life sciences and the financial industry by the help of the quarterly Life Sciences issues, the monthly digital newsletter LifeSciencesUpdate

SwissBiotech

www.swissbiotech.org

Swiss Biotech unites the four leading biotech regions of Switzerland (BioAlps, BaselArea, Biopolo Ticino and Greater Zurich Area). The regions have early on combined efforts with the SWX Swiss Exchange which holds a leading position in terms of life-science listings and services.

The National Industry Association named Swiss Biotech Association Represents more than 150 companies to date and acts as the operational arm for the marketing alliance. Swiss Biotech raises Switzerland's profile as an economic center in Europe and profiles the biotech industry with its key research institutions and companies.Swiss Biotechs' mission is to spread the message of Switzerland as one of the top biotech locations in the world. This will be achieved by presenting a comprehensive picture of the drivers of biotechnology including research, education, economics, finance and industry. The bases for success in biotechnology are the critical mass of research institutes and accelerated technology transfer. The early integration of industry and well-trained workforce is another critical success factor for rapid economic growth. More than 40 technology parks throughout the country support the increasingly important and successful TechTransfer process.

Tiberend Strategic Advisors, Inc.

www.tiberendstrategicadvisors.com

Tiberend Strategic Advisors, Inc. is a corporate communications firm providing media strategy and execution for life science companies – biotech (therapeutics), medical devices and diagnostics.We work with both public and private emerging growth companies:
1. To enhance valuation
2. To build visibility for partnerships and strategic alliances

SACHS ASSOCIATES

www.sachsforum.com

Sachs Associates is a long established international conference company with offices in Switzerland and the UK. It runs a limited number of high profile conferences in Europe and the USA which are focused on biopharma, medtech, and digital health. These conferences focus on licensing and investment opportunities and all provide presenting opportunities for companies and excellent meeting facilities for all delegates to network.

Sachs Associates is focused on the practical benefits accruing from conference participation, the exchange of ideas and information, and the facilitating of business transactions.

THE BENEFITS OF CONFERENCE PARTICIPATION WITH SACHS ASSOCIATES MAY BE SUMMARISED AS FOLLOWS:

ONLINE ONE-2-ONE MEETING SYSTEM

In order to offer the best possible provision for networking opportunities and deal making Sachs Associates provides all delegates access to our online One-2-One meeting system, allowing you to set up, accept or decline private One-2-One meetings with other conference attendees. These meetings last for 20 minutes in duration. Individual passwords and logins are provided to allow immediate access and ensure full security.

CUTTING EDGE CONTENT WITH EMINENT SPEAKERS

Sachs Associates is committed to ensuring that its events continue to provide forums with the participation of the most eminent speakers from the public and private sectors. Through its reputation and its long-established local relationships, the company has attracted very senior scientific and business personalities as speakers at its events.

SPONSORSHIP AND MARKETING OPPORTUNITIES FOR FORTHCOMING EVENTS

Sachs Associates has developed an extensive knowledge of the key individuals operating within the global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase your company position in this market. Sponsorship of any of our events allows you to raise your company's profile directly with your potential clients. All of our sponsorship packages are tailor-made to each client, allowing your organisation to gain the most out of attending our industry driven events.

THE FOLLOWING SPONSORSHIP AND MARKETING OPPORTUNITIES ARE AVAILABLE AT FUTURE CONFERENCES:

- Conference Sponsor – including workshops and social events
- Exhibition Stands
- Distribution of Promotional Material

If your company is interested in exhibiting or sponsorship opportunities, please call Silvia Kar on +44 203 463 4890 or email Silvia@sachsforum.com.


SACHS
ASSOCIATES
www.sachsforum.com